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ABSTRACT 
  
 Adoptive immunotherapy and oncolytic virotherapy are two promising strategies for 
treating primary and metastatic malignant brain tumors.  We demonstrate the ability of 
adoptively transferred tumor-specific T cells to rapidly mediate the clearance of established brain 
tumors in several mouse models.  Similar to the clinical situation, tumor recurrences are frequent 
and result from immune editing of tumors.  T cells can eliminate antigen-expressing tumor cells 
but are not effective against antigen loss variant (ALV) cancer cells that multiply and repopulate 
a tumor.  We show that the level of tumor antigen present affects the success of adoptive T cell 
therapy.  When high levels of antigen are present, tumor stromal cells such as microglia and 
macrophages present tumor peptide on their surface.  As a result, T cells directly eliminate 
cancer cells and cross-presenting stromal cells and indirectly eliminate ALV cells.  We were able 
to show the first direct evidence of tumor antigen cross-presentation by CD11b+ stromal cells in 
the brain using soluble, high-affinity T cell receptor monomers.  Strategies that target brain 
tumor stroma or increase antigen shedding from tumor cells leading to increased cross-
presentation by stromal cells may improve the clinical success of T cell adoptive therapies.   
 We evaluated one potential strategy to complement adoptive T cell therapy by 
characterizing the oncolytic effects of myxoma virus (MYXV) in a syngeneic mouse brain tumor 
model of metastatic melanoma.  MYXV is a rabbit poxvirus with strict species tropism for 
European rabbits.  MYXV can also infect mouse and human cancer cell lines due to signaling 
defects in innate antiviral mechanisms and hyperphosphorylation of Akt.  MYXV kills B16.SIY 
melanoma cells in vitro, and intratumoral injection of virus leads to robust, selective and 
transient infection of the tumor.  We observed that virus treatment recruits innate immune cells 
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to the tumor, induces TNFα and IFNβ production in the brain, and results in limited oncolytic 
effects in vivo.  To overcome this, we evaluated the safety and efficacy of co-administering 2C T 
cells, MYXV, and neutralizing antibodies against IFNβ.  Mice that received the triple 
combination therapy survived significantly longer with no apparent side effects, but eventually 
relapsed.  Based on these findings, methods to enhance viral replication in the tumor and limit 
immune clearance of the virus will be pursued.  We conclude that myxoma virus should be 
further explored as a vector for transient delivery of therapeutic genes to a tumor to enhance T 
cell responses.
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CHAPTER 1.  IMMUNOTHERAPY AND VIROTHERAPY FOR THE TREATMENT 
OF BRAIN TUMORS 
Brain Tumors:  A Clinical Challenge 
 Primary and metastatic brain tumors present significant challenges to patients and their 
physicians.  Approximately 50,000 Americans are diagnosed with malignant or non-malignant 
primary brain tumors annually1.  Depending on the tumor type, half of these cases are typically 
treatable with surgery, but the remainder have very poor prognoses2.  Brain metastases that arise 
from other cancers (most frequently lung, breast, melanoma, kidney, or colon) are estimated to 
occur in 170,000 patients annually3.  If untreated, patients have a median survival of only four 
weeks.  The overall five-year survival rate following diagnosis of a brain tumor is around 30%, 
but much less for highly malignant tumors1. 
 Most primary central nervous system (CNS) tumors develop from astrocytes, a type of 
glial cell.  Grade IV glioblastoma multiforme (GBM) tumors, the most malignant and most 
frequently diagnosed astrocytoma, are highly resistant to treatment4,5.  Patients with GBM 
tumors (gliomas) face a poor prognosis with a median survival of 12-15 months post-diagnosis 
and treatment6,7 and a five-year survival rate of only 3%1,8.  Standard treatments include surgery 
followed by chemotherapy and radiation therapy, but even aggressive multimodal treatments 
only extend survival for several months2,4,5.  The most significant advance for glioma treatment 
in the past 30 years is the addition of the chemotherapeutic agent temozolomide following 
surgical resection and fractionated radiation therapy.  When complete resection of the tumor is 
possible, treatment with temozolomide extends the median survival of patients over 55 years of 
age to 11 months and under 55 years to 18 months9.   
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 Gliomas are highly infiltrative and cancer cells can travel along axon tracts, vasculature 
and around ventricular spaces10.  Surgical excision often leaves behind malignant cells that have 
migrated several centimeters from the primary tumor mass.  Due to their heterogeneous makeup 
and genetically unstable nature11, some tumors become resistant to both irradiation and 
chemotherapeutic drugs12,13.  There is also growing evidence that the elimination of a small 
population of glioma stem cells that can repopulate a tumor is crucial to preventing tumor 
recurrence, and a subset of glioma stem cells (CD133+) are both chemoresistant and 
radioresistant14,15.   
 The incidence of secondary, or metastatic, CNS tumors is thought to be rising due to the 
improving effectiveness of cancer treatment in general.  Patients are surviving long enough to 
develop complications from metastatic tumors that arise when cancer cells spread via the blood 
or lymphatics.  15-40% of all patients with cancer, particularly lung and breast carcinomas and 
melanomas, develop metastatic brain tumors2,3.  Melanomas are most likely to metastasize to the 
brain over other sites, and patients with CNS involvement have very poor prognoses.  17-39% of 
patients with disseminated cutaneous melanoma develop multiple CNS metastases and without 
therapy, survive only 1-2 months16.  Whole brain radiation therapy can extend survival to four 
months, and combined with surgery to ten months.  However, even with the addition of systemic 
chemotherapy, these treatment combinations have not improved the overall outcome.  Due to the 
improved clinical responses observed in patients with GBM tumors, temozolomide is now being 
evaluated for treatment of patients with metastatic melanoma brain tumors17. 
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The Immune System Response to Brain Tumors 
 The immune system has evolved to defend against invading pathogens and altered cells, 
including cancer cells.  However, CNS tumors are a challenging target.  Both innate and adaptive 
immune cells should prevent tumor development by recognizing and eliminating mutated cells, 
yet in most types of cancer there are subtle distinctions at the molecular level between normal 
and malignant ‘self’ cells.  Immune cells such as T cells that react strongly with ‘self’ peptides 
are typically deleted in the thymus during development to prevent autoimmunity.  Furthermore, 
most immune cells must also migrate to the brain to locate malignant cells and then overcome 
local immunosuppressive mechanisms.  Circulating immune cells have limited access to the 
brain under normal conditions and inflammation is actively suppressed, leading to the 
historically misleading description of the brain as immune-privileged18.  In non-pathological 
states, or in early stages of tumor development, the brain is better characterized as quiescent.  
The blood-brain barrier (BBB) generally limits circulating antibodies and unactivated 
lymphocytes from entering the CNS19.  Inflammation is actively suppressed in normal brain 
tissue by soluble and cellular mediators including TGF-β, IL-10, prostaglandins (PGE2) and 
gangliosides, resulting in an environment that hinders or delays immune reactivity19.  Despite its 
normal quiescence, both innate and adaptive immune responses do occur in the brain during 
infection and injury, in autoimmune diseases such as multiple sclerosis, and in brain tumors.  
However, the suppressive environment of the CNS and tumor-induced immune defects often 
result in tumor escape.      
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Innate Immune Responses to Brain Tumors 
 Over the lifespan of an individual, the frequency at which transformed or malignant cells 
are quickly eliminated by the immune system before a tumor can establish is unknown, but likely 
numerous.  Innate immune cells are considered the first responders to developing tumors.  NK 
cells and macrophages can respond quickly to stress-induced proteins expressed on tumor cells.  
Upregulated ligands such as MHC class I chain-related molecules A and B (MICA/B) and UL16-
binding proteins are recognized by NKG2D receptors on NK cells and macrophages, making 
glioma cells susceptible to killing20,21.  NK cells can also detect the loss of class I major 
histocompatability complex (MHC) expression on transformed cells and kill them either directly 
by releasing granules containing perforin and granzymes, or indirectly by secreting cytokines 
such as interferon-γ (IFNγ) to activate other innate immune cells and sensitize the cancer cells 
for apoptosis or killing22.  Macrophages kill tumor cells by releasing nitric oxide and TNF-α19,23, 
phagocytose dead and dying tumor cells, and secrete cytokines such as IL-12 that recruit and 
activate monocytes and T cells. 
 Microglia, the resident phagocytic macrophage-like cells of the brain, accumulate in 
brain tumors in large numbers in response to chemokines secreted by the tumor24 and have both 
anti-tumor and pro-tumor functions.  Cells with macrophage and microglia surface markers 
represent approximately one-third of all cells in glioma biopsies25,26 and between 5-35% of the 
total tumor burden in experimental rodent glioma models24,27.  In their resting state, microglia 
survey the brain parenchyma and become activated in response to CNS damage28,29.  In their 
activated state, microglia differentiate into effector cells and phagocytose dead or dying cells, 
secrete pro- and anti-inflammatory cytokines and neurotrophic factors, and induce a non-specific 
inflammatory state29-33.  Microglia also have the ability to act as antigen presenting cells (APCs) 
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and can activate CD4+ helper T cells by expressing tumor peptides bound to MHC class II 
molecules and costimulatory molecules such as CD80 and CD8634,35.  Macrophages/microglia 
also cross-present tumor peptides on MHC class I to activate cytotoxic CD8+ T cells36-39.   
 
Adaptive Immune Responses to Brain Tumors 
 In general, tumor rejection is largely dependent on activated T cells and their secreted 
products40, and some studies indicate the presence of tumor-infiltrating T cells in malignant 
gliomas is associated with longer survival41,42.  The CNS lacks traditional lymphatics,  but 
cervical lymph nodes collect CNS antigens that drain along cranial nerves and subarachnoid 
space and through the cribiform plate43.  T cells circulate between blood and lymph until they are 
activated by APCs presenting CNS antigens in cervical and possibly other peripheral lymph 
nodes44.  Upon co-stimulation by APCs, T cells respond to their antigen by acquiring an 
activated phenotype and proliferating.  Activated T cells can traffic to the brain and adhere to 
endothelium to extravasate across the BBB into brain tissue45.  Once activated, CD8+ T cells are 
capable of recognizing and killing cancer cells expressing their cognate antigen bound to MHC 
class I molecules by direct contact mechanisms (e.g. perforin, granzyme, FasL, TRAIL).  
Activated CD4+ helper T cells also traffic to brain tumors46and play an important role in anti-
tumor immunity by recognizing antigen presented by APCs on MHC class II molecules, 
secreting cytokines (e.g., IFNγ), and expressing surface molecules (e.g., CD40L) to directly 
activate APCs and indirectly activate CD8+ T cells.  In contrast to their classical characterization 
as support cells for CD8+ T cells and APCs, a new appreciation for CD4+ T cell orchestration of 
the overall anti-tumor immune response and their direct cytotoxic effects on tumor cells is 
emerging47-49. 
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 T cell responses are highly antigen-specific and MHC-restricted.  Within a polyclonal 
population of CD8+ T cells, each clone will only recognize and kill cancer cells expressing 
peptide/MHC antigens recognized by their unique T cell receptor (TCR).  Effector CD8+ T cells, 
also called cytotoxic T lymphocytes (CTLs), require presentation of their antigen on class I 
MHC molecules.  Brain tumor cells express low levels of MHC I, in part due to normally low 
expression by brain cells50, but also from presentation pathway defects in cancer cells51.  CD8+ T 
cells may also recognize antigen presented by phagocytic cells that internalize and process tumor 
proteins, and cross-present them on MHC I.  CTLs can kill tumor cells and cross-presenting 
APCs directly or indirectly by secreting cytokines to recruit other cells (macrophages, NK cells, 
etc.).  A number of human glioma- and melanoma-associated antigens recognized by CD8+ 
TCRs have now been identified including MHC I (HLA-A02 allele) restricted IL-13Rα, HER-2, 
gp100, MAGE-1, EGFRvIII, and others (reviewed in 7). 
 
Immune Defects Associated with Brain Tumors 
 Immune surveillance mechanisms may be intact, but the effector response to brain tumors 
is typically insufficient, at least at the point of clinical detection.  A large percentage (11-72%) of 
glioma specimens are reported to have T cell infiltrates42,52,53, and this finding is not unique to 
gliomas.  For example, patients with progressively growing metastatic melanomas have had 
frequencies of Melan-A/MART-1-specific CD8+ T cells as high as 1% in peripheral blood, but 
are unable to reject established tumors54.  
 Brain tumors escape detection, attack, and elimination by activated T cells through a 
variety of soluble and cell-associated mechanisms present in both draining lymph nodes and 
locally in the tumor7,55.  Activated T cells that traffic to a glioma or melanoma brain tumor 
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encounter a local suppressive environment characterized by expression of TGF-β, IL-10, 
prostaglandin E2,  indoleamine-2,3-dioxygenase (IDO) and other inhibitory molecules that 
inhibit proliferation and cytotoxic activity and can induce anergy or apoptosis56-61.  Tumor-
infiltrating CD4+ lymphocytes often adopt a Th2 phenotype, produce IL-4 and GM-CSF rather 
than IL-2 and IFN-γ62, dampening the CTL response.   
 Glioma and metastatic melanoma brain tumors also possess mechanisms to avoid T cell 
cytotoxicity by expressing apoptosis or tolerance-inducing ligands (e.g., FasL, PD-L1)61,63,64, 
inducing anergy through lack of co-stimulatory molecule expression (e.g., B7)65, and 
downregulating or expressing altered MHC66,67.  Notably, engagement of the inhibitory 
programmed death (PD-1) receptor on T cells by its ligand PD-L1 expressed by many human 
cancers including melanoma appears to have a significant inhibitory effect on T cell effector 
function68,69. 
 T cells can be suboptimal for executing tumor cytotoxicity even without tumor-induced 
suppression.  Most tumor antigens are derived from altered or overexpressed normal proteins.  If 
endogenous T cells recognize overexpressed ‘self’ tumor antigens via their TCR and become 
activated, it is usually via a low affinity interaction, as highly avid TCR-bearing T cells are 
deleted during development to prevent autoimmunity70.  In addition, afferent immune responses 
from the brain occur through drainage of antigens to cervical lymph nodes, which tend to bias 
CD4+ T cell responses towards a Th2, or immunosuppressive phenotype71.  Tumor-specific T 
cells found in patients and animal models also exhibit signaling defects involved in activation 
and are more likely to undergo apoptosis72-74.   
 CD4+CD25+ regulatory T cells (Treg), a subset of CD4+ T cells, are major contributors to 
maintaining peripheral tolerance by immune cells to normal tissues, but also contribute to the 
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immune evasion of brain tumors by suppressing effector T cells through secretion of TGFβ and 
IL-10 and direct cytolysis75.  Treg cells are increased in the blood and tumors of patients with 
gliomas and melanomas76,77, and in animal models64,78-80.  Depletion of Treg cells leads to 
prolonged survival in animal models80,81.     
 In cases where T cell effector functions are intact and effective, tumor heterogeneity due 
to genetic instability or immune editing (elimination of antigen-positive but not antigen-negative 
cancer cells) can lead to outgrowth of antigen loss variant (ALV) cancer cells which are no 
longer recognized by CTLs82,83.  ALVs are a significant cause for concern in all cases where a 
single tumor antigen is targeted. 
 Defects in innate immunity against brain tumors also play a role in immune escape.  
Glioma cells avoid cytolysis by NKG2D receptor-expressing NK cells and macrophages by 
secreting TGF-β and matrix metalloproteinases that downregulate MICA and UL16 binding 
proteins84.  One immunohistological study showed that only 9% of malignant gliomas contained 
NK cells46, perhaps due to this ligand downregulation. 
 Microglia and macrophages are recruited to brain tumors to participate in the repair of 
local tissue damage and the anti-tumor immune response85, but can also support the growing 
tumor58,86.  Microglia are known to suppress T cells through multiple mechanisms including 
FasL expression, prostaglandin E2, and IL-10 production55,87,88.  In fact, microglia have been 
shown to be the major source of IL-10 in tumors87.  IL-10 supports enhanced proliferation and 
infiltration of tumor cells58 and promotes MHC downregulation and reduced antigen presentation 
by microglia89.  Microglia also produce the cysteine protease cathepsin B and vascular 
endothelial growth factor (VEGF) that promote tumor invasion and angiogenesis90,91. 
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 The evolution and accumulation of many selective advantages for immune escape by 
tumors suggest that the immune cells can initially be sufficient for controlling tumor growth.  
However, once tumors reach a certain size and degree of heterogeneity (correlating with 
diagnostic grade), various mechanisms have tipped the balance in favor of tumor escape.  Our 
growing understanding of these mechanisms of immune suppression and methods to overcome 
them, especially within the brain, support the pursuit of therapies that can tip the balance back in 
favor of immune control. 
 
Immunotherapies for Brain Tumors 
   Important developments over the past several decades include improved brain imaging 
and surgical methods, targeted radiation treatment, and better chemotherapeutic drugs with fewer 
side effects.  Yet even with an aggressive approach of removing substantial amounts of brain 
tissue, these therapies have failed to significantly improve the survival outcome for patients with 
gliomas and metastatic brain tumors, and often lead to impaired cognition, sensory and motor 
deficits, seizures, and other serious complications92.  Following treatment, relapse and death are 
attributed to progressive growth of minimal residual disease.  Thus, complementary treatments 
that target minimal residual disease are urgently needed.  Strategies that harness the sensitivity, 
specificity and cytotoxicity of immune cells by tipping the balance in favor of an effective 
immune response remain very attractive.   
 Active, passive and adoptive immunotherapy strategies are potentially useful approaches 
and have been successful in preclinical studies, but have only modestly improved survival in 
clinical trials thus far.   Further developments using animal tumor models are improving our 
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understanding of the requirements for successful immunotherapy, gene therapy, oncolytic 
virotherapy, and other novels forms of treatment for brain tumors. 
 
Active Immunotherapy 
 Active immunotherapy involves generating a host immune response against known or 
unknown tumor antigens through vaccination.  By exploiting the efficient antigen presentation 
capabilities of dendritic cells (DCs), due in part to their abundant expression of co-stimulatory 
molecules, tumor vaccines can effectively prime CD4+ and CD8+ effector T cells.  Vaccination is 
typically accomplished by injecting (often with cytokines) irradiated tumor cells, tumor peptides, 
or DCs pulsed with acid-eluted tumor peptides or tumor lysate.  Sampson and colleagues showed 
that systemic vaccination of mice with irradiated, cytokine-producing (IL-3, IL-6, or GM-CSF) 
melanoma cells followed by intracranial challenge with melanoma cells protected mice and led 
to improved survival that was CD8+ T cell dependent93.  Soon after, Ashley et al. were the first 
to show that DCs pulsed with melanoma cell extract or melanoma RNA and injected into mice 
with established intracranial melanoma tumors were able to prime cytotoxic T cells and extend 
survival significantly94.  Similar results have also been observed in a mouse glioma model after 
mice were injected with DCs pulsed with tumor homogenate95.  Treatment improved the median 
survival and memory T cells were generated that protected against later intracranial challenge in 
mice that were cured.       
 Vaccination has shown good efficacy in mouse brain tumor models but smaller successes 
in patients thus far.  Two strategies currently in clinical trials include intradermal injections of 
tumor cell lysate-pulsed DCs (DCVaxTM, Phase I/II) or DCs loaded with tumor-associated 
peptides derived from EGFR variant III (CDX-110TM, Phase II/III).  Recent data reported by 
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Northwest Biotherapeutics, Inc. on the DC VaxTM trial are very impressive:  the median survival 
of GBM patients was over 36 months and 22% of patients have survived greater than six years.  
The CDX-110TM vaccination protocol uses a peptide derived from an overexpressed mutant 
epidermal growth factor receptor (EGFRvIII) found on 24-67% of glioblastomas96,97 and shows 
strong objective responses in an ongoing Phase II trial.  All patients had EGFRvIII-specific 
immune responses and 18 of the 23 recurrent tumors that were studied no longer expressed 
EGFRvIII98, indicating the need to target additional or multiple tumor-specific antigens. 
 An important consideration regarding vaccination is the potential to induce autoimmunity 
if vaccine peptides are not tumor-specific and induce T cell responses against normal tissue.  In a 
non-CNS mouse tumor model, vaccination with tumor-associated peptides that were also 
expressed on normal tissue (pancreas, smooth muscle, cardiomyocytes) resulted in tumor cures 
but also severe autoimmunity (diabetes, arteritis, cardiomyopathy)99.  For CNS antigens, Bigner 
and colleagues showed that lethal experimental autoimmune encephalomyelitis (EAE) was 
induced in nonhuman primates after injection of human glioma tissue and complete Freund’s 
adjuvant, an immune booster comprised of mycobacterial components100.   
 Many preclinical and clinical vaccination strategies are promising, but demonstrate the 
challenge of overcoming tumor editing by T cells leading to ALVs.  For vaccine strategies to be 
effective, they must also induce a strong immune response that persists indefinitely until the 
tumor is eliminated.  Concerns about the induction of autoimmunity by cellular vaccines has 
generated interest in other tumor-specific approaches including passive treatment with tumor-
specific antibodies or adoptive transfer of tumor-specific T cells.     
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Passive Immunotherapy 
 Passive immunotherapy involves the administration of molecules, typically antibodies, to 
elicit tumor cytotoxicity.  The recipient does not have to be fully immune-competent, which 
bears importance for glioma patients who often have low peripheral numbers of B cells and 
helper CD4+ T cells101.  In addition, antibodies are not susceptible to soluble tumor-suppression 
mechanisms and provide an advantage over cell-based therapies.   
 Examples of passive immunotherapy involve injection of unlabeled antibodies into the 
resected tumor cavity to elicit antibody dependent cellular cytotoxicity (ADCC) by phagocytic 
immune cells bearing Fc receptors, or the use of radiolabeled or toxin-linked antibodies to 
localize their cytotoxic effects.  Monoclonal antibodies against the extracellular matrix protein 
tenascin (131I labeled) and EGFR (wild type or mutant vIII), both overexpressed in gliomas, have 
been best characterized and show some modest increases in survival time when administered 
intratumorally102.  Passive immunotherapeutic approaches have potential because they avoid the 
need to overcome defects in priming the immune system.  However, they face other challenges 
such as production of human anti-mouse antibodies (HAMA) which may prohibit a patient from 
receiving multiple rounds of treatment.  Recombinant DNA technology or chimeric 
mouse/human antibodies can circumvent this problem.  Other challenges include identification of 
truly tumor-specific antibodies to prevent damage to healthy tissue and delivery of sufficient 
doses to invasive brain tumor locations.  
 
Adoptive T Cell Therapy 
 A third immunotherapeutic approach and the focus of our research involves the transfer 
of antigen-specific cellular immunity conferred by T cells.  Tumor-specific T cells can be 
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isolated, activated and expanded ex vivo, and then re-infused back into a patient either 
intravenously or directly into the tumor cavity.  The motility, sensitivity, specificity, and 
cytotoxic effector function of T cells make adoptive therapy an excellent candidate for targeting 
invasive, surgically inaccessible disease and micrometastases within the brain, while causing 
minimal collateral damage to healthy brain tissue.   
 Adoptive therapy has a number of significant advantages over other forms of 
immunotherapy.  T cells can be expanded ex vivo away from tolerizing or inhibitory conditions 
and subsequently retain cytolytic ability in vivo103.  Anergic (unresponsive) T cells can be 
rescued by IL-15 exposure prior to adoptive transfer104.  Furthermore, effector T cells can be 
introduced into a patient or tumor-bearing animal in larger numbers (1010-1011) than may be 
possible to generate by active vaccination strategies.  As a result, robust T cell priming in a 
potentially immune-compromised patient is unnecessary.  In addition, genes encoding T cell 
receptors recognizing glioma and melanoma tumor-associated antigens have been identified and 
transduced into human T cells105-107.  These engineered lymphocytes have been shown to persist 
in patients and mediate tumor regression.  The ability to transduce peripheral blood T cells with 
antigen-specific TCRs eliminates the need to identify and expand tumor-specific T cells from 
patients, a slow and labor-intensive process.  Recent identification of many additional glioma- 
and melanoma-associated antigens will undoubtedly aid the search for TCRs appropriate for 
treating brain tumors in this way.    
 The use of lymphocytes to treat brain tumors is not new.  Observations 35 years ago that 
leukocytes were cytotoxic to glioblastoma cells in culture108 led to an early clinical trial by 
Young and colleagues.  Patients with GBM tumors with life expectancy under one month were 
enrolled and several dramatic clinical responses were observed109.  Patients were injected 
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intratumorally with autologous leukocytes from peripheral blood.  Almost 50% of the patients 
(8/17) in this study had clinical improvement, although no survival benefit.  In one remarkable 
case, a 49-year old man diagnosed with GBM underwent surgical resection, radiotherapy, and 
chemotherapy but deteriorated rapidly five months after treatment.  He was readmitted to the 
hospital comatose, and a CT scan showed tumor growth.  Following injection of 5 x 107 
autologous leukocytes into the tumor, improvements were noted within 5 hours.  In three days, 
he was walking and eating and remained well for 17 months.  It is not known what roles the 
mixed immune cells in this preparation played in the observed responses, but this trial provided 
proof-of-concept for further adoptive immunotherapy studies.   
 Different sources of T cells have been used for preclinical and clinical adoptive therapy 
studies including peripheral blood, tumor or vaccine draining lymph nodes, lymphokine 
acitivated killer (LAK) cells, tumor-infiltrating lymphocytes (TILs), and most recently 
genetically engineered T cells transduced to express TCRs that recognize cancer antigens105-
107,110-116.  Discovery of the T cell growth factor IL-2 led to the ability to expand and activate 
lymphocytes in culture.  High concentrations of IL-2 produce LAK cells, which can be expanded 
and activated in vitro and subsequently re-infused back into brain tumor-bearing animals or 
patients in combination with IL-2 treatment117-124.  A few instances of improved survival with 
LAK cell treatment have been observed123,124, especially with intracavitary brain injections, but 
concerns about overall efficacy121, IL-2 toxicity119, non-specific killing, and poor trafficking to 
the brain have generally shifted interest towards using tumor-specific T cells or TILs.   
 Tumor draining lymph nodes and lymph nodes receiving antigen from subcutaneous 
vaccinations with irradiated tumor cells or peptide-pulsed DCs both contain T cells that have 
been sensitized to tumor antigens.  Although preparations of these T cells were unable to cure 
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tumor-bearing recipient mice after adoptive transfer, ex vivo activation with IL-2, anti-CD3, and 
superantigens such as staphylococcal enterotoxin was effective in eliciting anti-tumor effector 
function after adoptive transfer into mice with established brain tumors110,125-128. 
 The combination of vaccination followed by adoptive immunotherapy with T cells from 
peripheral blood or tumor draining lymph nodes is in clinical development.  Wood and 
colleagues have immunized patients with irradiated, autologous tumor cells and collected 
peripheral blood to activate and expand lymphocytes with anti-CD3 and IL-2 ex vivo115.  1010-
1011 cells were reinfused back into patients resulting in regression of three of nine patients’ 
tumors.  Remarkably, two patients were still alive four and five years later.  Another trial using a 
similar protocol in combination with high dose chemotherapy for recurrent pediatric brain 
tumors resulted in tumor-specific immune responses in all patients and ongoing survival at two 
years129.  Similar trials by Sloan et al. saw 8/19 partial responses with activated T cells purified 
from blood after vaccination116 and Plautz et al. observed 4/12 partial responses using T cells 
from vaccine draining lymph nodes113, but survival times were not increased in either study.   
 Ex vivo activation of T cells is an effective method to generate in vivo anti-tumor effector 
function, but to date, this approach has been generally insufficient to produce cures in patients.  
This may be due, in part, to the inclusion criteria of the clinical trials.  All but the Plautz study 
treated patients that failed to respond to multiple previous forms of therapy.  Patients also were 
not lymphodepleted prior to adoptive therapy, an important criterion for the success of adoptive 
therapy for metastatic melanoma (see below).  Furthermore, no effort was made in these studies 
to isolate and expand TILs or highly reactive tumor-specific T cells. 
 According to the NIH clinical trials database, there are three active trials using adoptive T 
cell therapy for malignant glioma (www.clinicaltrials.gov, accessed 11/17/09).  Two of these 
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trials employ T cells recognizing a viral antigen from cytomegalovirus (CMV).  A high 
percentage of human gliomas have been reported to be infected with CMV130, implying that viral 
epitopes could also serve as immunotherapeutic targets.  It remains to be seen if highly reactive 
T cells recognizing any of the recently identified glioma-specific antigens (IL-13Rα2, gp100, 
MAGE-1, EGFRvIII, etc.) can be translated into clinical success.    
 Adoptive T cell therapy for brain tumors has a long history of sporadic responses, and 
lags behind more promising results for other solid peripheral tumors, particularly melanomas.  
Steven Rosenberg and colleagues at the National Cancer Institute were the first to show that 
adoptive transfer of TILs purified from resected melanomas, expanded in vitro, and injected back 
into patients concurrently with high doses of IL-2 produced some responses in patients with 
metastatic melanomas refractory to other treatments131,132.  A major problem noted was the 
disappearance of adoptively transferred cells, presumably due to competition with endogenous T 
cells for cytokines required for survival (e.g., IL-7 and IL-15).  Subsequent studies evaluated 
adoptive T cell therapy combined with lymphodepleting chemotherapy that allowed homeostatic 
repopulation with tumor-specific T cells, increased persistence of T cells in circulation, and 
depleted Treg cells.  This protocol has resulted in 50% objective clinical results in patients with 
metastatic melanoma, including responses to brain metastases, and some complete responses 
have apparently been achieved132,133.  Yee and colleagues have observed similar encouraging 
results after adoptive transfer of CD8+ T cells specific for two melanoma-associated antigens 
with systemic low dose IL-2, and reported 8/10 partial or stable responses in patients with 
metastatic disease134.  Most recently, a protocol that includes lymphodepletion with fractionated 
total body irradiation and non-myeloablative chemotherapy prior to T cell transfer with 
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concurrent IL-2 treatment has shown a 72% objective response rate and metastatic tumors are 
cleared from multiple tissues including brain135.   
 Adoptive T cell therapy seems to be well-tolerated overall, with the major complications 
stemming from IL-2 toxicity, lymphodepletion-related viral and bacterial infections, and 
autoimmune reactivity to normal melanocytes.  Recently, adoptive transfer of TCR-transduced, 
highly reactive T cells resulted in autoimmune complications involving the eye, inner ear, and 
skin producing hearing loss, anterior uveitis, and vitiligo107,132.  These patients required treatment 
with corticosteroids and most symptoms resolved.  Further studies characterizing the ideal 
transduced T cell population for therapeutic use are underway136.    
 T cell adoptive therapy is a promising approach for treatment of melanomas, gliomas and 
other cancers, but the current challenge remains to translate sporadic responses into frequent and 
widespread responses.  Isolation and clonal expansion of tumor-specific T cells are time-
intensive and complex processes.  Patients may not have CTLs with sufficient avidity for tumor 
antigens, or their tumors may lack immunogenic antigens to generate CTLs.  This can be 
overcome by searching for T cell clones from other individuals that demonstrate tumor 
reactivity, cloning the TCR genes, and expressing them in T cells isolated from a patient.  
Another approach involves generating CTL clones through immunization of transgenic mice 
expressing human HLA (MHC I) molecules with human tumor antigens or tumor cells. Mouse 
TCR genes can be isolated from tumor-reactive T cells and transduced into human T cells for 
adoptive therapy107. Fortunately, TCR-transduced T cells do seem to persist in vivo and retain 
both proliferative and cytotoxic abilities106,137.   
 To date, reliable transduction of autologous T cells using viral vectors encoding tumor-
specific TCRs has been accomplished in only a few laboratories.  The use of retroviral and 
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lentiviral vectors to transduce genes for the alpha and beta chains of tumor antigen-specific 
TCRs must proceed cautiously to prevent chain mispairing with endogenous TCRs and potential 
autoimmunity.  Chimeric antigen receptors (CARs) that fuse the antigen-binding regions of a 
monoclonal antibody with the CD3 signaling domain of the TCR may circumvent this problem.  
CARs targeting IL-13Rα, which is overexpressed on greater than 80% of human gliomas but 
absent from normal CNS tissue, have been used successfully to treat xenograft models of 
glioma138 and demonstrated antitumor effects in one case study of a GBM patient105.    
 Clinical use of adoptive T cell therapy for brain tumors still faces several hurdles 
including sufficient trafficking to the tumor, persistence of transferred cells, overcoming Treg-
mediated suppression, and heterogeneous tumor antigen expression.  Activated T cells must also 
be able to resist tumor-suppressive mechanisms (TGFβ, IL-10, IDO, FasL, PD-L1, etc.).  
Adjunct therapies may be necessary to inhibit these mechanisms.  For example, humanized anti-
PD-1 antibodies are currently being evaluated in a Phase I clinical trial139.  CD4+CD25+ Treg cells 
may also need to be actively excluded from T cell preparations to promote tumor rejection.    
 Clearance of heterogeneous tumors like gliomas will likely require T cells specific for 
several tumor antigens to prevent the outgrowth of antigen loss variant cancer cells.  CD4+ T 
cells that recognize MHC class II bound antigens on tumor stromal cells could expand the 
number of potential tumor targets significantly.  The importance of tumor-specific CD4+ T 
helper cells to promote tumor clearance is gaining appreciation48,140-142.  CD4+ T cells may act as 
cytotoxic effector cells themselves48,143 or as support cells to CD8+ T cells via production of 
IFNγ and APC activation.   
 In cases of a strong antitumor response, T cells can ‘edit’ the tumor by selectively killing 
cells that express antigen while ignoring ALVs134.  This is likely to become a major obstacle as 
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more T cell clones with high avidity for tumor-associated antigens are used for adoptive transfer 
studies in patients.  Preclinical studies have characterized some factors that improve the anti-
tumor effects of adoptive therapy and prevent tumor recurrence from ALVs.  For example, work 
from our laboratory suggests that increasing cross-presentation of tumor antigen on tumor 
stromal cells improves the effectiveness of adoptive T cell therapy by eliminating the stromal 
support cells for ALVs (39 and Chapter 2).  T cell-based therapies in combination with other 
strategies, including the approach of combining T cell therapy with oncolytic virotherapy 
described in Chapter 3, may also overcome these challenges.  
 
Oncolytic Virotherapies for Brain Tumors 
 The potential use of viruses to treat cancer was recognized over 100 years ago when 
cancer regression was observed in patients that developed viral diseases or were inoculated with 
viral vaccines.  Reports of clinical use of oncolytic viruses began in the 1950s, with some 
sporadic tumor regressions observed in patients injected with Hepatitis B virus, West Nile virus, 
and adenovirus (reviewed in 144 and 145).  These observations, combined with the development of 
in vitro virus propagation methods and advances in molecular biology for characterizing viral 
genetics and pathogenesis, have led to the present-day investigation of dozens of viruses for their 
oncolytic potential. 
 Oncolytic viruses are replication-competent viruses that selectively infect and kill 
malignant cells by exploiting genetic mutations in cancer cells that permit viral entry and/or viral 
replication146,147.  Productive replication leads to amplification of viral titer within a tumor and 
virus can spread between neighboring tumor cells.  Preclinical models and clinical trials have 
evaluated many families of viruses including adenoviruses, herpesviruses, poxviruses, 
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parvoviruses, reoviruses, orthomyxoviruses, paramyxoviruses, rhabdoviruses, picornaviruses and 
others.  For treatment of gliomas, four viruses have completed testing in Phase I clinical trials:  
two herpes simplex virus (HSV) mutants148,149, a mutant adenovirus (ONYX-015)150, a reovirus 
(REOLYSIN)151, and two strains of Newcastle disease virus152,153.  Some of these viruses are 
normally pathogenic in humans and have been attenuated with various mutations to limit the 
infectivity of normal cells.  All were shown to be safe in patients with occasional objective 
responses (some are summarized below).  Clinical trials using vaccinia virus, poliovirus, and 
measles virus for treating malignant gliomas are also ongoing. 
 Martuza and colleagues developed the HSV virus mutant G207 with mutations in both 
copies of a neurovirulence gene that conditionally replicates in dividing cells but not in normal 
brain cells154,155.  G207 is also touted as safe because of its susceptibility to ganciclovir and 
acyclovir (anti-viral drugs) to treat HSV encephalitis, if it were to develop.  Preclinical studies 
demonstrated the efficacy of G207 against intracranial human xenograft tumors in a mouse 
model155.  G207 was also well-tolerated by non-human primates156.  A phase I clinical trial 
published in 2000 showed patient tolerance of up to 3x109 pfu (plaque forming units) injected 
intratumorally into gliomas with no dose-limiting toxicity, and there was some evidence of anti-
tumor activity and long term presence of viral DNA148.  One patient remains alive almost six 
years after treatment.  A follow-up trial showed that multiple doses of virus can be safely 
delivered directly to brain tumor cavities via a catheter157.  A second similar HSV mutant, 1716, 
showed no rate-limiting toxicity in nine patients in a phase I clinical trial and tumor biopsies 
recovered virus at higher titers than the injected dose149.  A phase II trial showed responses in 
two of 12 patients158.  Phase III clinical trials are underway in Europe.   
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 A conditionally replicative adenovirus, ONYX-015, was one of the first viruses to show 
good clinical success and was approved in China for the treatment of head and neck cancer 150.  
Disappointingly, ONYX-015 does not seem to be as effective for gliomas.  It was originally 
thought that ONYX-015 could not replicate in cells with functional p53 tumor suppressor 
molecules, but tumor cells with non-functional p53 would allow viral replication and lysis159.  
However, a subsequent study showed that the anti-tumor efficacy of ONYX-015 in a human 
xenograft glioma mouse model was independent of p53 status160.  Despite this preclinical study 
showing efficacy, a phase I clinical trial of intratumoral injection in gliomas showed no 
significant responses in 24 patients and 96% of patients had disease progression.  However, none 
of the patients had an adverse response to the virus and three patients that received the highest 
titers were alive at 19 months follow-up150.  The case of ONYX-015 illustrates that human 
xenograft brain tumors growing in immune-compromised mice do not necessarily predict the 
success of virotherapies in patients, nor does the success of an oncolytic virus for treating one 
type of cancer necessarily transfer to other types of cancer.   
 With dozens of candidate viruses being studied, it remains to be seen which will be most 
successful for treating malignant brain tumors.  The most important feature of these viruses 
(other than efficacy) must be safety.  Some candidate oncolytic viruses cause disease in non-
human hosts, but have the benefit of being nonpathogenic in humans.  Viruses such as Newcastle 
disease virus (NDV), vesicular stomatitis virus, and myxoma virus can infect and kill human 
cancer cells by exploiting their altered signaling pathways, and may be potentially safer and 
more potent than human viruses because attenuation is unnecessary.  A Phase I /II clinical trial of 
patients with GBM evaluated the oncolytic effects of NDV, an avian virus, delivered 
intravenously.  Three of 14 patients survived 15 months after treatment, but no long term 
 22
survival was attained153.  However, another study describes four patients that have survived long-
term (five to nine years) following treatment with a different NDV strain152.     
 
Poxviruses and Virotherapy 
 Poxviruses are candidates for both oncolytic virotherapy and gene therapy due to their 
large, double-stranded DNA genomes that allow the insertion of eukaryotic genes161,162.  Gene 
delivery by poxviruses is considered safe because they replicate in cytoplasm and do not 
integrate their DNA into the host cell genome.  Poxviruses can replicate in about 24 hours, with 
early gene expression starting within two to four hours after cell entry163, making them ideally 
suited to deliver genes for immunomodulators or tumor antigens that get expressed before the 
infected cell dies.  The short replication time also leads to rapid spread of virus in vivo.  
   Vaccinia, the most well-known member of the large poxvirus family, was most famously 
used in humans as a live vaccine to eradicate smallpox.  Vaccinia virus infects multiple species 
including humans, but replicates more efficiently in rapidly dividing cells such as those found in 
tumors164.  Leaky tumor vasculature is important for the accumulation of systemically delivered, 
relatively large (~200nm) virus particles.  In animal models, vaccinia accumulates in multiple 
tumor types after systemic delivery, with low yield in most other tissues.  However, vaccinia 
does collect and replicate in highly vascularized tissues such as the ovaries, producing concern 
regarding its use in patients165,166.  Attenuated vaccinia viruses, such as thymidine kinase 
knockouts, have reduced ability to replicate in normal tissues167.  A recombinant vaccinia virus 
expressing p53, IL-2 and IL-12 was shown to inhibit rat C6 glioma growth in vivo, although 
some cytokine toxicity was observed168.  Recombinant vaccinia virus encoding GM-CSF has 
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been evaluated for the treatment of cutaneous and metastatic melanoma, with some clinical 
responses169,170.        
 Other poxviruses considered for cancer therapy with tropism for species other than 
humans include yaba-like disease virus (primate), canarypox virus, fowlpox virus, and myxoma 
virus (rabbit).  Myxoma virus has demonstrated oncolytic effects in vitro in many permissive 
human cancer cell lines including melanoma and glioma, making myxoma virus an attractive 
candidate for treatment of brain tumors in vivo171,172.  In contrast to vaccinia, humans lack pre-
existing immunity against myxoma virus that could eliminate the virus before carrying out its 
oncolytic and gene delivery functions.    
 
Myxoma Virus 
 Myxoma virus is a rabbit poxvirus with a strict species tropism for European rabbits and 
a small number of other lagomorphs.  Myxoma virus infection results in a fatal disease called 
myxomatosis for European rabbits, but is abortive in other species164,173-175.  The stringent host 
specificity of myxoma virus was the basis of efforts to eradicate feral rabbits in Australia in the 
1950s and resulted in 99% reduction in the rabbit population with no evidence of infection in 
other native species or in humans176.  In fact, historical data indicate that humans living in very 
close contact with infected rabbits and mosquitoes, the natural vectors of the virus, do not show 
evidence of infection or produce antibodies against myxoma virus177.  Virally encoded rabbit-
specific immunomodulators enhance the ability of myxoma virus to replicate in rabbit cells, but 
its tropism for cancer cells seems to be related instead to defective antiviral defenses and 
signaling pathways in transformed cells (discussed below). 
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 In the last five years, myxoma virus has shown oncolytic effects on many human and 
mouse cancer cell lines.  Sypula and colleagues tested the oncolytic effects of myxoma virus on a 
National Cancer Institute collection of human cancer lines derived from various tissues and 
found that myxoma virus could kill 15/21 lines including melanoma171.  Subsequent studies have 
shown human glioma, pancreatic adenocarcinoma, medulloblastoma and rhabdoid tumor cells 
are permissive to infection and killing172,178-180.  Most recently it was discovered that myxoma 
virus can selectively target human leukemic stem cells while sparing normal stem cells, an 
exciting strategy that may allow purging of leukemic progenitors from autologous blood and 
marrow ex vivo before grafting back into patients with acute myelogenous leukemia that were 
lymphodepleted with chemotherapy181.    
 
Mechanisms of Tumor-Selective Infection by Oncolytic Viruses 
 Oncolytic viruses utilize two main mechanisms that determine tropism for tumor cells.  
First, most viruses enter cells by binding to specific cell surface viral receptors.  Several of these 
proteins are overexpressed on many cancer cell types.  For example, intracellular adhesion 
molecule (ICAM) and decay accelerating factor (DAF) serve as viral receptors for 
Coxsackievirus A21, and ICAM/DAF expression levels on melanoma cells correlate with 
infection and oncolysis by this virus182.   
 In addition to receptor overexpression, tumor selectivity by oncolytic viruses is strongly 
related to aberrant signaling pathways found in cancer cells.  For example, endogenous Type I 
interferon (IFNα and IFNβ) anti-viral and anti-proliferative signaling pathways are disrupted in 
many cancers183,184.  Several oncolytic viruses have now been shown to exploit this defect and 
productively replicate in malignant cells185-187, but not in normal cells of the same tissue, or in 
 25
permissible tumor cells treated with IFN-α185.  Other antiviral pathways are also mutated in 
cancer cells.  dsRNA viruses such as reovirus can infect cells with a common cancer mutation 
involving Ras that lack an enzyme that suppresses translation of viral proteins188.  
 In contrast to some oncolytic viruses, binding and entry by poxviruses into mammalian 
cells is generally not restricted at the cell surface level.  Until recently, the mechanism of cellular 
entry by the well-characterized vaccinia virus was still unknown.  Mercer et al. determined that 
vaccinia induces cellular uptake via endocytosis triggered by exposed phosphatidylserine 
residues on the viral membrane, mimicking absorption of apoptotic cells189.  The uptake 
mechanism of myxoma virus is still unknown, but the specificity of both vaccinia virus and 
myxoma virus for cancer cells is probably not at the level of cell entry.  Instead, normal cells can 
abort the replication cycle of the virus, while signaling defects in cancer cells permit productive 
viral replication.  These defects have been linked to impaired Type I interferon responses in 
mouse cancer cells186,190, and dysregulated activation of Akt kinase in human cancers191,192.   
 Cell culture experiments with mutant myxoma viruses lacking different host range genes 
revealed that one gene product significantly affects whether human cancer cells are permissive to 
infection171,191.  M-T5 protein is necessary for viral replication in CD4+ rabbit T cells and the 
development of myxomatosis in rabbits.  M-T5 also forms complexes with two human 
intracellular proteins:  Cullin-1 and Akt-1193.  The interaction of M-T5 with Cullin-1, an E3 
ubiquitin ligase involved in cell cycling, prevents cell cycle arrest and apoptosis to allow viral 
replication.  Upon binding Akt, M-T5 activates Akt, an important serine/threonine kinase 
involved in survival, proliferation and cell death.  Permissiveness of myxoma infection is 
directly dependent on activation (phosphorylation) of Akt.  Many human cancers exhibit 
hyperactivated Akt, and viral M-T5 interactions with Akt allows some non-permissive cancer 
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cells with lower levels of Akt phosphorylation to become permissive to myxoma infection192.  
The molecular mechanism of Akt/MT-5 interaction is under active investigation164,194.  
  McFadden and colleagues have also demonstrated that rapamycin, a potent inhibitor of 
mTOR signaling and a cancer chemotherapeutic, also increases the permissiveness of some 
cancer cells in vitro179,195.  Using siRNA knockdown of signaling proteins, Stanford et al. have 
shown that rapamycin binding to its target mTORC1 leads to increased replication of myxoma 
virus that correlates with Akt activation196.  Treatment of semi-permissible, but not fully 
permissible or non-permissible, human cancer cells with rapamycin increases viral replication 
and spread in vitro195. However, treatment of non-cancerous cells (e.g., human fibroblasts) with 
rapamycin does not lead to infection164.  Rapamycin may become an important enhancer of 
oncolytic virotherapy in vivo179,197-200. 
 
In Vivo Tumor Treatment with Myxoma Virus 
 Myxoma virus was initially tested in vivo using human glioblastoma cell line xenografts 
after it was shown to infect and kill several human glioma cell lines in vitro172.  Myxoma virus 
demonstrated extremely potent antitumor activity in orthotopic mouse brain tumor models, as 
well as fresh human glioma explants.  Intratumoral injection of myxoma virus into established 
U87 or U251 human gliomas growing in nude mice (lacking T cells) resulted in the selective and 
persistent infection of tumors that progressively shrank and eventually cured 92% of mice172.  
Injection of live virus into the brains of nude mice was safe and remained tumor-restricted, 
peaking in titer at two weeks in nude mice.  Histologic examination revealed minimal 
inflammation but the authors noted that some lymphocytes and microglia/macrophages were 
present172.    
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 These provocative findings were also extended to a murine model of metastatic 
melanoma using immune-competent mice.  B16-F10 melanoma cells are highly permissive for 
myxoma virus infection and replication, and multiple intravenous injections of virus 
demonstrated therapeutic effects against B16-F10 lung metastases200.  Concurrent treatment with 
rapamycin reduced the size and number of metastases, and importantly, reduced the antiviral 
neutralizing antibody titers.    
 Myxoma virus oncolysis of human and mouse glioma and melanoma cancer cells holds 
promise as an effective virotherapy for malignant brain tumors.  However, the immunogenicity 
of myxoma virus in the brains of immunocompetent mice or humans has not been characterized 
and may limit efficacy.  However, combined with other conventional therapies or 
immunotherapy, myxoma virus may expand the available treatment options for malignant brain 
tumors. 
 
Statement of Problem and Research Significance 
 Adoptive immunotherapy and oncolytic virotherapy are two strategies that have provided 
encouraging but infrequent successful outcomes for patients with malignant brain tumors.  
Current standard-of-care treatments require the combination of surgery, chemotherapy, 
radiotherapy, and temozolomide to extend patient survival approximately one year.  Single 
modes of therapy are not effective.  The complex pathology of brain tumors (and cancer in 
general) will likely continue to require multimodal treatments incorporating new strategies that 
target minimal residual disease.  Both adoptive T cell therapy and oncolytic virotherapy 
complement standard treatments and have significant potential to improve the overall outcome.   
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 Promising results from adoptive therapy clinical trials for metastatic melanoma provide 
momentum to further develop this strategy for treatment of brain tumors.  Careful attention to the 
isolation and adoptive transfer of an appropriate subset of glioma antigen-specific T cells and 
lymphodepletion prior to transfer are likely to improve the effectiveness of adoptive therapy for 
GBM patients.  Current challenges in the field relate to the identification of this subset and the 
factors that influence the success or failure of these cells to eliminate tumors in the brain.  These 
issues can be readily examined in murine brain tumor models.  For example, factors that prevent 
or allow selective immune editing of a brain tumor resulting in antigen loss variant cells need to 
be further characterized.  These issues can be evaluated in tumor-bearing mice using tumor-
specific T cells in our model systems.  
  A large body of work by Hans Schreiber and colleagues using peripheral tumor models 
indicates that tumor stromal cells play a critical role in T cell-mediated tumor rejection, 
including the elimination of ALV cancer cells201-205.  Tumor stroma includes the endothelial 
cells, fibroblasts, macrophages/microglia, and extracellular matrix proteins that support growth 
and tissue invasion by a tumor.  Subcutaneous tumors in mice that express high levels of tumor 
antigen are rejected by antigen-specific T cells while the same T cells fail to eliminate low-
expressing tumors due to ALV cells204.  The elimination of ALV cells from high antigen-
expressing tumors was found to depend on the ability of CD11b+ macrophage stromal cells to 
cross-present antigen to T cells.  T cells directly eliminated both cancer cells and cross-
presenting stromal cells, indirectly preventing ALV cells from growing out, and resulted in 
complete cures in mice.  Furthermore, low antigen-expressing tumors could be eliminated 
following treatment with chemotherapy or local irradiation.  These treatments were found to 
induce loading of antigen onto stromal cells, and produced tumor rejection similar to that of 
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high-expressing tumors205.  Whether similar mechanisms relate to T cell rejection of tumors 
growing in the CNS with a different population of stromal cells were unknown.  These questions 
were the basis of studies outlined in Chapter 2.     
The second major focus of this research was to evaluate the combination of adoptive T 
cell therapy and oncolytic virotherapy with myxoma virus as a potential synergistic approach for 
treating malignant brain tumors.  Myxoma virus is highly effective at eliminating orthotopic 
human glioma cells growing in immunocompromised nude mice172.  To our knowledge, there 
has been no characterization of the oncolytic effects of myxoma virus in immunocompetent, 
syngeneic mouse brain tumor models that may respond quite differently to viral challenge.  This 
is an important issue considering that many therapies appear to be very efficient in xenograft 
tumor models but do not reliably translate to clinical use.   
We evaluated the oncolytic effects of myxoma virus in vitro and in vivo using a 
syngeneic mouse melanoma brain tumor model.  We also characterized the immune response to 
viral infection of murine brain tumors and evaluated a combination therapy of T cell adoptive 
transfer, injection of myxoma virus, and cytokine neutralization.  Our results in the syngeneic 
brain tumor model using the same initial inoculum of myxoma virus differ significantly from the 
potent killing observed in xenograft models, and suggest that syngeneic tumor models may more 
accurately reflect the local environment that oncolytic viruses encounter in immune-competent 
patients.  
 
2C T Cell System and Brain Tumor Models 
2C T Cell System 
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 To study cytotoxic T cell responses to brain tumors in vivo, our laboratory works with a 
well-characterized CD8+ T cell clone called 2C that was originally isolated 25 years ago206.  The 
2C T cell receptor (TCR) recognizes and binds several defined peptide antigens bound to either 
allogeneic H-2Ld or syngeneic H-2Kb class I MHC molecules (Figure 1.1).  There are many 
useful reagents related to this defined system.  1B2, a monoclonal antibody against the 2C TCR, 
can be used to identify 2C T cells by flow cytometry or immunohistochemistry.  Biotinylated 
soluble single-chain high affinity mutant TCR monomers called 2C-m67 (Figure 1.2) can be 
used to detect the model peptide antigen SIYRYYGL bound to H-2Kb at very low concentrations 
with a KD of approximately 16 nM207.  2C TCR transgenic mice on the C57BL/6 background and 
2C TCR mice backcrossed with recombinase-activating gene-1 knockout (RAG1-/-) mice that 
lack B and T cells express the 2C TCR on approximately 80% or 100% of their CD8+ T cells 
respectively.  Lymphocytes from these mice can be collected and used for tumor-specific 
adoptive immunotherapy in recipient mice with brain tumors.   
 
Brain Tumor Models 
 The 2C TCR binds to the Kb-bound peptide ligand SIYRYYGL (referred to as SIY) that 
acts as the model tumor antigen in this system with a KD of approximately 32 μM207 (Figure 
1.1).  We used several mouse cancer lines that stably express SIY/Kb complexes to establish 
tumors by intracranial infusion into syngeneic C57BL/6 or C57BL/6 RAG1-/- mice.  MC57 is a 
fibrosarcoma cell line that expresses either high (MC57-SIY-Hi) or low (MC57-SIY-Lo) levels 
of SIY/Kb expressed as a fusion protein with enhanced green fluorescent protein (eGFP)205.  
PRO4L is a fibrosarcoma/spindle cell line that expresses high levels of SIY and eGFP, but 
expresses MHC class I H-2k. SIY peptide does not bind Kk, so 2C T cells do not directly 
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recognize PRO4L-SIY cells201.  However, 2C T cells may recognize SIY peptide derived from 
PRO4L-SIY tumors when it is cross-presented on Kb molecules by brain tumor APCs39.   
T cell adoptive therapy studies using mice with these different SIY-expressing brain 
tumors are outlined in Chapter 2.  In an effort to develop immunotherapies using realistic models 
that encompass many features of malignant brain tumors, a murine melanoma cell line was used 
for the studies in Chapter 3.  The B16.SIY melanoma brain tumor model was chosen because it 
accurately reflects the clinical situation in many ways.  Both tumors are highly aggressive and 
anti-tumor immune responses are insufficient due in part to low surface levels of tumor antigen 
and class I MHC expression.   
 The parental B16-F10 melanoma cell line was originally derived from a spontaneously 
arising melanoma in a C57BL/6 mouse and thus has an MHC class I H-2b haplotype208.  Later, 
B16.SIY cells were engineered to stably express SIY peptide bound to Kb, making them 
recognizable to 2C transgenic T cells.  Retroviral transduction was used to introduce cDNA 
encoding SIY peptide fused in frame with enhance green fluorescent protein (GFP)209 similar to 
the MC57-SIY cell lines.  Fluorescence activated cell sorting for GFP-positive cells selected 
cells that expressed high levels of the fusion protein.  Some downward drift in GFP fluorescence 
over time has been observed, so highly positive cells have been re-selected several times.  
B16.SIY melanoma cells are poorly immunogenic and express low to absent levels of class I 
MHC without IFNγ treatment209.  SIY/Kb complexes on B16.SIY cells are detectable by 2C-m67 
TCR monomers following IFNγ treatment (unpublished data). 
  B16-F10 and B16.SIY tumors grow very aggressively.  C57BL/6 mice infused in the 
brain with 1x103 B16.SIY cells (Figure 1.3) have a median survival of only 16 days210.  In vitro 
killing assays and adoptive transfer of 2C T cells into minor histocompatability mismatched 
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129S6 mice with B16.SIY brain tumors revealed poor cytotoxic effector function by 2C T 
cells209,210.  However, IFNγ upregulation of class I MHC expression on the cancer cells could 
improve the 2C T cell killing response in vitro.  Much improved effector function (cytolysis) by 
2C T cells against B16.SIY cells was observed upon blocking PD-1, a cell surface inhibitory 
receptor of T cell activation that interacts with PD-L1 on B16.SIY cells 209.  This suggests that 
given proper activation (e.g., IFNγ) and removal of tumor suppression (e.g., PD-L1) on B16.SIY 
cells, 2C T cell responses to melanoma brain tumors could be augmented in vivo.  We are the 
first to evaluate this model using wild-type C57BL/6 mice instead of 129S6 mice that are able to 
reject B16.SIY as a subcutaneous tumor but not in the brain210. 
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CHAPTER 1 FIGURES 
 
 
Figure 1.1 
T cell/cancer cell interaction.  Transgenic CD8+ 2C T cells express the heterodimeric α and β 
subunits of the 2C T cell receptor (TCR) that recognizes SIYRYYGL peptide bound to the class 
I major histocompatibility (MHC) molecule H-2Kb on the surface of mouse cancer cells. 
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Figure 1.2 
A soluble, single-chain monomer comprised of the variable regions of the 2C TCR high 
affinity mutant m67.  2C-m67 recognizes SIY peptide bound to MHC class I H-2Kb on cancer 
cells or APCs with low nanomolar affinity.  Monomers were chemically biotinylated at multiple 
sites via free amine groups. 
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Figure 1.3 
Growth timecourse of B16.SIY brain tumors in mice.  Syngeneic B16.SIY melanoma brain 
tumors following intracranial injection of 2 x 103 cells into ventral striatum.  Day 3, bilateral 
injections.  Days 10 and 15, unilateral injection. 
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CHAPTER 2.  RECURRENCE OF INTRACRANIAL TUMORS FOLLOWING 
ADOPTIVE T CELL THERAPY CAN BE PREVENTED BY DIRECT AND INDIRECT 
KILLING AIDED BY HIGH LEVELS OF TUMOR ANTIGEN CROSS-PRESENTED ON 
STROMAL CELLS1 
 
Abstract 
 Elimination of peripheral tumors by adoptively transferred tumor-specific T cells may 
require killing of cancer cells and tumor stromal cells.  Tumor antigens are cross-presented on 
stromal cells resulting in direct cytotoxic T cell (CTL) killing of both antigen-expressing cancer 
cells and stromal cells.  Indirect killing of antigen loss variant cells (ALVs) also occurs.  We 
show here that similar processes occur in a brain tumor stromal environment.  We employed 
murine cancer cell lines that express high or low levels of a peptide antigen, SIYRYYGL (SIY) 
recognized by transgenic 2C CD8+ T cells.  The two cell lines were killed with equivalent 
efficiency by 2C T cells in vitro.  Following adoptive transfer of 2C T cells into mice with 
established SIY-Hi or SIY-Lo brain tumors, tumors of both types regressed but SIY-Lo tumors 
recurred.  SIY-Hi tumors contained CD11b+ cells cross-presenting SIY peptide and mice were 
cured following adoptive transfer.  To further test the role of cross-presentation, RAG1-/- H-2b 
mice were infused with H-2k tumor cells expressing high levels of SIY peptide.  Adoptively 
transferred 2C T cells are able to kill cross-presenting H-2b stromal cells but not H-2k tumor 
cells.  In peripheral models this paradigm led to a small static tumor.  In the brain, activated 2C T 
cells were able to kill cross-presenting CD11b+ cells and completely eliminate the H-2k tumors in 
                                                 
1 Figures and text in this chapter are published in the Journal of Immunology 2009, 183(3):1828-37 with permission 
to reprint here.  Copyright 2009.  The American Association of Immunologist, Inc.   
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most mice.  Targeting brain tumor stroma or increasing antigen shedding from tumor cells to 
enhance cross-presentation may improve the clinical success of T cell adoptive therapies. 
 
Introduction 
T cell-mediated immunotherapies for cancer currently in development include 
vaccination strategies and adoptive transfer of tumor-specific T cells (reviewed in 1-3).  The 
results of clinical trials evaluating adoptive T cell therapies have been mixed, with particular 
types of cancer showing some beneficial response.  Treatment of melanoma in particular shows 
promise 4-6, but antigen loss variant (ALV) cancer cells remain a challenge for antigen-specific T 
cell therapies 5,7.   
Adoptive T cell therapies for brain tumors have also been investigated for more than 25 
years in animal models 8-15 and in clinical trials 16-26.  Early trials used activated T cell 
populations that were not specific for tumor antigens, but more recent preclinical studies have 
outlined approaches to improve the effectiveness of adoptively transferred antigen-specific T 
cells 27-37.  Clinical trials evaluating autologous, ex vivo activated T cells from peripheral blood 
or tumor- or vaccine-draining lymph nodes have demonstrated partial responses against gliomas, 
even in patients that previously failed to respond to multiple forms of therapy 20,21,26,38. 
Tumors outside the central nervous system are easily accessed by primed CTLs, but even 
in cases of strong anti-tumor responses, it is clear that new approaches for targeting ALV cancer 
cells that lead to tumor recurrence are needed to improve the success of T cell-based therapies 
5,7,39,40.  Similarly, T cell responses can also be induced in the brain following peptide 
vaccination targeting EGFRvIII on malignant gliomas, but EGFRvIII negative tumors recur in 
patients 41.   
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Successful clearance of solid peripheral tumors and prevention of relapse from ALV 
outgrowth depend on elimination of malignant cancer cells as well as bone-marrow and non-
bone-marrow-derived stromal cells that support the growing tumor 42-47.  Adoptively transferred 
CTLs can target both cancer cells and stromal cells that cross-present tumor peptides shed by 
cancer cells or internalized via phagocytosis.  ALV cancer cells sheltered within the tumor 
stroma can be eliminated via a bystander effect by killing cross-presenting CD11b+ stromal cells 
that are sensitized with sufficient tumor antigen released by dying cancer cells, irradiation, or 
chemotherapy 46.    
The importance of targeting stroma has previously been established for a variety of 
peripheral tumors 42-47, but brain tumor stroma differs from other tissues in several ways.  For 
example, gliomas do not induce lymphangiogenesis 48 and microglia associated with gliomas are 
particularly active at secreting TGFβ that contributes to invasiveness 49.  Gliomas are also 
comprised of different stromal elements than peripheral tumors.  Fibroblasts contribute to T cell-
mediated peripheral tumor rejection 44.  However, fibroblasts are absent from gliomas and 
orthotopic murine brain tumors 50. 
 Differences in brain and peripheral immune responses to tumors, and in the stroma of 
brain and peripheral tissues, led us to investigate whether cross-presentation of brain tumor 
antigens by stroma is also important for brain tumor rejection by adoptively transferred CTLs.  
Mice were intracranially infused with cancer cells expressing high or low levels of a defined 
model peptide antigen, SIYRYYGL (SIY).   High- and low-antigen expressing cell lines have 
been shown to have differences in ALV outgrowth in subcutaneous models 46.  Tumors were 
allowed to establish for several days before treatment to allow tumor stromal cells to organize.  
Mice received an adoptive transfer of 2C T cells that recognize SIY peptide presented on MHC I 
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haplotype Kb and T cell responses to both tumors were characterized.  Cross-presentation of 
tumor antigens by CD11b+ brain tumor stromal cells was directly assessed using high affinity 
single-chain T cell receptor (TCR) monomers that bind tumor peptide/MHC complexes.  We also 
observed anti-tumor effects of adoptively transferred 2C T cells when stromal cross-presentation 
was the only mechanism of peptide/MHC presentation in the tumors.  
 
Methods 
Mice, Cell Lines, and Reagents 
 C57BL/6 RAG1-/- mice from The Jackson Laboratory are maintained as a colony at the 
University of Illinois.  2C TCR transgenic mice are maintained as a heterozygous colony by 
crossing with C57BL/6 mice and screened for expression of the 2C TCR on peripheral blood 
leukocytes (PBLs) by flow analysis with 1B2 clonotypic antibody.  Mice were 2–6 months of 
age at the time of experiments. All procedures were approved by the Institutional Animal Care 
and Use Committee at the University of Illinois at Urbana-Champaign.   
 MC57-SIY-Lo and MC57-SIY-Hi cells (derived from C57BL/6 mouse fibrosarcoma 
MC57), and PRO4L-SIY and PRO4L-gp33 cells (derived from C3H/HeN mouse 
undifferentiated spindle cell cancer 1591-PRO4L) were generated at the University of Chicago 
and have been described previously 45,51,52.  Cancer cells were grown in complete RPMI 1640 
medium containing 5 mM HEPES, 10% FCS, 1.3 mM L-glutamine, 50 pM 2-ME, penicillin, and 
streptomycin.   
 Anti-Kb and isotype control antibodies were purchased from eBiosciences and anti-CD31 
(PECAM-1) from Pharmingen.  1B2 monoclonal antibody specific for the 2C TCR was purified 
from the hybridoma and biotinylated in our laboratory.  Expression and purification of soluble, 
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single-chain 2C-m67 TCR monomers that bind SIY/Kb with low nanomolar affinity were 
described previously 46.  Monomers were chemically biotinylated at multiple sites via free amine 
groups using EZ-Link NHS-PEO4 Biotinylation Kit (Pierce).  Streptavidin-allophycocyanin (SA-
APC, Invitrogen) was used as a fluorescently labeled secondary reagent.   For flow cytometry 
experiments, cancer cells were stained and washed twice with PBS/BSA before analysis on a BD 
FACS Canto or BD LSR II.  
 
In Vitro Cytotoxity Assay 
 2C T cells from spleens of 2C TCR transgenic mice were prepared by mechanical 
dissociation and ammonium chloride buffer lysis of erythrocytes.  Splenocytes were incubated 
for 48 hours with 3 μM SIY peptide (SIYRYYGL) and 10 ng/mL murine rIL-2 (R&D Systems) 
to activate effector 2C T cells.  Target cancer cells were incubated with 100 μL of 2 mCi/mL 
51Cr for two hours at 37°C and washed three times before incubating with 2C T cells at different 
effector-to-target ratios for four hours.  Chromium release was measured using a Beckman 
gamma counter and specific release was calculated using the standard formula:  ((sample counts-
spontaneous counts)/(maximum counts-spontaneous counts))*100. 
 
Cancer Cell Infusion and T Cell Adoptive Transfer 
 Cancer cells were trypsinized and collected, washed twice with Hanks Balanced Salt 
Solution, and stereotaxically infused into the brain.  Each mouse received an infusion of 5 x 104 
cells in 300 nL in ventral striatum (AP 0.5mm, lat 2.5mm, DV -4mm).  In all experiments unless 
specified otherwise, a small tumor challenge of approximately 1-2 x 105 cells was prepared the 
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same way and injected subcutaneously into the flank to ensure peripheral afferent immune 
responses leading to activation of adoptively transferred 2C T cells.   
 2C T cells were adoptively transferred by preparing a single cell suspension of lymph 
node and spleen cells from 2C TCR transgenic mice, lysing erythrocytes with ammonium 
chloride buffer, and washing twice with HBSS.  Mice were injected with 5 x 107 naive 2C 
lymphocytes into the tail vein one, five, six or ten days after tumor implantation.  
 
Histological Analysis of T cell Response 
 Mice were sacrificed at one, three, or five days following 2C T cell transfer or followed 
for survival.  Criteria for euthanasia were 75% of baseline body weight or signs of neurological 
impairment, in accordance with IACUC guidelines.  To identify 2C T cells, unfixed frozen 10 
micron tissue sections were stained with 1B2 antibody amplified with HRP/tyramide-biotin 
(Perkin Elmer) and streptavidin-Alexa 594 (Invitrogen), and counter-stained with DAPI 
(Invitrogen).  Other sections were stained with anti-CD31 (PECAM), followed by biotinylated 
rabbit anti-rat IgG (Vector) and streptavidin-Alexa 594 to detect endothelial cells.  Tumor 
volume was systematically reconstructed by measuring tumor area on hematoxylin stained 
sections taken at regular intervals through the brain. 
 
Analysis of Cross-Presentation by CD11b+ Stromal Cells 
 CD11b+ cells were purified from MC57, MC57-SIY-Lo, MC57-SIY-Hi brain tumors 
(established for 10 days before adoptive transfer of 2C T cells) and PRO4L-SIY brain tumors 
(established for seven days before adoptive transfer of 2C T cells) two or three days following 
2C T cell adoptive transfer using anti-CD11b-labeled magnetic beads (Miltenyi).  Brains tumors 
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were dissected, minced, and incubated with Dispase (Gibco, 5U/mL) at 33°C for 30 min in 
Hibernate A media (BrainBits).  Cells were then washed with RPMI media containing 10% FCS 
to inactivate Dispase and pushed through 100 μm and 40 μm filters sequentially.  Erythrocytes 
were lysed with ammonium chloride buffer and cells were washed with Hibernate A before 
following the manufacturer’s protocol for separation of CD11b+ cells using a magnetic column.  
Purified cells were then stained with anti-CD11b-Pacific Blue (Caltag Laboratories), 2C-m67 
TCR detected with streptavidin-Alexa594, and/or propidium iodide (1 μg/mL, BD Pharmingen) 
and analyzed on a BD LSR II flow cytometer.   
 
Statistical Analyses 
 GraphPad Prism software was used to analyze survival curves by Logrank test and 
area/volume data by unpaired T test.   Significance was considered p < 0.05.  
 
Results 
Cancer cell lines expressing different surface levels of SIY peptide are killed equally well by 
2C T cells in vitro  
 MHC I haplotype Kb expression on MC57 cancer cell lines was evaluated to rule out that 
differences in surface levels of MHC I result in differences in killing by CD8+ 2C T cells.  All 
three MC57 lines (parental, SIY-Lo, SIY-Hi) express similar levels of Kb (Figure 2.1A).  We 
also confirmed that PRO4L-SIY cancer cells (H-2k) do not express Kb.  Next we measured the 
relative surface levels of SIY peptide complexed with Kb on the cancer cells using biotinylated 
single-chain high-affinity 2C TCR monomers (2C-m67 TCR).  2C-m67 TCR binding was 
detected with fluorescent streptavidin-APC.  The mean fluorescence intensity of MC57-SIY-Lo 
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cells was increased approximately 2.6-fold over untransduced MC57 parental cells.  MC57-SIY-
Hi cell levels were increased approximately 16-fold over MC57-SIY-Lo cells (Figure 2.1B).   
Enhanced GFP (eGFP) and SIY are expressed as a fusion protein in the construct used to 
generate these cell lines, therefore eGFP levels can also serve as an index of SIY antigen 
expression.  The mean eGFP fluorescence of MC57-SIY-Lo and MC57-SIY-Hi cancer cells 
were 1.6 and 17-fold over untransduced parental MC57 respectively (Figure 2.1C).  PRO4L-
SIY cells express the highest level of eGFP, but SIY cannot be presented on H-2k and thus is not 
recognized by the wild-type 2C TCR or single-chain high affinity 2C-m67 TCR monomers.  
eGFP expression serves as the only relative readout of SIY peptide present in PRO4L-SIY 
cancer cells. 
Next we evaluated the cytotoxic effector function of 2C T cells against the MC57 cancer 
cell lines in vitro using a chromium release killing assay.  Equivalent 51Cr release was measured 
from MC57-SIY-Hi and MC57-SIY-Lo cells incubated with preactivated 2C T cells at different 
effector to target cell ratios (Figure 2.1D).  The parental MC57 line was poorly killed by 2C T 
cells, demonstrating specificity for the SIY antigen.  In a separate assay, PRO4L-SIY showed 
low levels of chromium release similar to parental MC57 when incubated with activated 2C T 
cells, confirming the MHC restriction of the 2C TCR to Kb (data not shown). 
 
Adoptively transferred 2C CTLs initially cleared established brain tumors expressing high or 
low levels of antigen 
To establish an in vivo brain tumor model to assess the therapeutic effect of adoptively 
transferred tumor-specific 2C T cells, we infused MC57, MC57-SIY-Lo and MC57-SIY-Hi 
cancer cells into the brains of syngeneic C57BL/6 RAG1-/- mice and waited several days for the 
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tumor and stroma to establish.  Unactivated, naïve 2C T cells were adoptively transferred into the 
tumor-bearing mice on day 5.  On the same day, a small number of the same cancer cells was 
injected subcutaneously to ensure a robust afferent immune response and activation of the 
transferred 2C CTLs.   
One day following treatment, there were few 2C T cells infiltrating either SIY-Hi or SIY-
Lo brain tumors (Figure 2.2A), and both tumors were well-established and growing (Figure 
2.3A).  Three days following transfer of 2C T cells, both MC57-SIY-Hi and MC57-SIY-Lo 
tumors were infiltrated by massive numbers of 2C T cells (Figure 2.2B).  Five days following T 
cell transfer, both tumor types were almost completely eliminated based on histological 
examination (Figure 2.3B).  2C T cell accumulation was still observed at the sites of both SIY-
Hi and SIY-Lo tumors (Figure 2.2C), but there was little evidence of residual tumor.  In these 
brains, T cells were mostly restricted to the tumor hemisphere but not restricted to the tumor, 
raising some concern about autoimmunity.  However, brain histopathology was unremarkable 
and long-term survivors showed no evidence of behavioral abnormalities at any point.  
Impressively, MC57-SIY-Hi tumors were almost completely eliminated within two days of the 
surge of T cell infiltration despite a faster growth rate than MC57-SIY-Lo (Figures 2.3C and 
2.3D, note difference in Y-axis scale).  This faster growth rate was also observed in cell culture 
(data not shown). 
If the subcutaneous injection of cancer cells to activate the transferred 2C T cells was 
omitted, some 2C T cells infiltrated both SIY-Hi and SIY-Lo brain tumors by day 5, but the 
response was greatly diminished (Figure 2.2D).  We also observed that 2C T cells activated by a 
subcutaneous injection of MC57-SIY-Hi cells were able to infiltrate parental (SIY-negative) 
MC57 tumors in the brain (Figure 2.2E), suggesting local inflammatory cues existed that 
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recruited the activated 2C T cells.  However, the possibility that transgenic 2C T cells expressing 
an additional endogenous TCR that may have recognized other tumor antigens cannot be ruled 
out.  Compared to MC57-SIY-Hi or SIY-Lo brain tumors, substantially fewer 2C T cells were 
retained in parental MC57 brain tumors at five days post-transfer (Figure 2.2E compared to 
Figure 2.2C) and the tumors grew out.   
 
In a unilateral brain tumor model, adoptively transferred 2C CTLs completely eliminated SIY-
Hi brain tumors and cured mice while mice with SIY-Lo tumors usually relapsed 
Experiments following mice for survival outcome were done to determine if tumor-
infiltrating 2C CTLs were able to completely cure mice with brain tumors expressing high or low 
levels of SIY peptide.  Mice with five day-old unilateral MC57-SIY-Hi, MC57-SIY-Lo, or 
MC57 parental brain tumors received unactivated 2C T cells and a small subcutaneous injection 
of the same cancer cells to ensure activation of the transferred cells.  Subcutaneous cancer cells 
did not grow out.  2C T cell treatment cured 100% of mice with MC57-SIY-Hi tumors and 
significantly extended survival of mice with MC57-SIY-Lo tumors (median survival 46 days vs. 
17 days with no 2C transfer, Figure 2.4A).  Mice with MC57-SIY-Lo brain tumors that reached 
criteria for euthanasia were confirmed to have recurring brain tumors post-mortem.  Mice with 
either MC57-SIY-Hi or MC57-SIY-Lo brain tumors that did not receive 2C T cells survived 
similarly as mice with parental MC57 brain tumors treated with 2C T cells (median survival 
times of 16, 17, and 18 days, respectively, Figure 2.4A).   
 
In a bilateral brain tumor model, adoptively transferred 2C CTLs eliminated SIY-Hi tumors 
but failed to eliminate SIY-Lo tumors 
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To evaluate whether ineffective priming or cytotoxic effector function of adoptively 
transferred 2C T cells were responsible for the observed relapses of mice with MC57-SIY-Lo 
brain tumors, additional survival experiments were done to determine if 2C CTLs could clear 
both SIY-Hi and SIY-Lo brain tumors present in the same mouse.  MC57-SIY-Hi and MC57-
SIY-Lo cells were infused bilaterally into the brains of mice. Mice received 2C T cell transfers 
and subcutaneous injections of both SIY-Hi and SIY-Lo cancer cells bilaterally to activate the 
CTLs five, six or ten days later to determine any effect of timing.  In Figure 2.4B-D, each mouse 
that received 2C T cells is represented by two curves, showing survival time dependent on which 
brain tumor recurred.  Brains of mice that reached criteria for euthanasia were histologically 
examined post-mortem to determine which tumor had recurred.  When 2C T cell adoptive 
transfers were given on day 5, MC57-SIY-Hi tumors were eliminated in all mice, indicating that 
the 2C CTLs had been sufficiently activated and were able to kill (Figure 2.4B).  However, two 
of five mice died from recurring MC57-SIY-Lo tumors even though MC57-SIY-Hi tumors were 
rejected in the same mice.    
The timing of adoptive transfer with respect to tumor growth was critical.  Control mice 
with bilateral tumors that did not receive 2C T cell treatment survived only 14 days (Figure 
2.4B-D).  Mice receiving 2C T cells on day 5 following cancer cell infusion included three long 
term survivors (out of five), and all mice rejected MC57-SIY-Hi tumors (Figure 2.4B).  Mice 
receiving 2C T cells on day 6 did not survive, but death was significantly delayed by 2C T cell 
treatment (Figure 2.4C).  In four of five cases, recurring MC57-SIY-Lo tumors were responsible 
for the relapse and MC57-SIY-Hi tumors were eliminated.  If 2C T cell treatment was given on 
day 10 (i.e. only a few days before mice normally succumb to the tumors) both MC57-SIY-Hi 
and MC57-SIY-Lo tumors continued to grow and were rapidly fatal (Figure 2.4D).  Presumably 
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CTL killing cannot keep up with the rapidly dividing cancer cells once the tumor reaches a 
critical mass.  In this regard, it is important to note that by day 12 following cancer cell infusion, 
tumor masses occupied more than 50% of the brain hemisphere in some coronal planes assessed 
by MRI (data not shown). 
 
Adoptively transferred 2C T cells persist in vivo but no longer recognize MC57-SIY-Lo brain 
tumors that recur due to antigen loss 
To address the possibility that adoptively transferred 2C T cells did not persist in mice 
with MC57-SIY-Lo brain tumors that recurred, we examined tumors, draining cervical lymph 
nodes and spleen tissue collected from mice when they reached criteria for euthanasia.  1B2 
antibody staining revealed substantial numbers of 2C T cells in recurring brain tumors and 
lymphoid tissue of all mice evaluated 34 or 35 days following adoptive transfer of 2C T cells 
(Figure 2.5, n=3).   
To determine whether the recurring MC57-SIY-Lo brain tumors were SIY-antigen loss 
variant cells no longer recognized by 2C T cells, tumors were excised from mice (n=5) when 
they reached criteria for euthanasia following relapse (31 to 51 days following 2C T cell 
transfer).  All mice had received 2C T cell transfers and subcutaneous cancer cell injections on 
day 5.  Tumor explants were dissociated and then cultured for several days to enrich for live 
cancer cells.  Explanted tumor cells were then stained with anti-Kb monoclonal antibody and 
analyzed by flow cytometry.  All recurring tumors expressed normal levels of MHC I-Kb 
(Figure 2.6A).  To detect surface levels of SIY peptide bound to Kb, explanted cancer cells were 
also stained with biotinylated single-chain 2C-m67 TCR monomer (Figure 2.6B).  Flow analysis 
revealed that levels of 2C-m67 TCR binding to explanted tumor cells were similar to SIY-
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negative parental MC57 tumor cells, indicating that recurring MC57-SIY-Lo tumors developed 
from SIY-loss variants not recognized by 2C T cells.   
 
CD11b+ stromal cells in brain tumors expressing high levels of antigen cross-present tumor 
peptide on MHC I 
We hypothesized that one possible mechanism by which adoptively transferred 2C T 
cells can eliminate SIY-Hi but not SIY-Lo brain tumors may be related to stromal cell cross-
presentation of available tumor antigen to CTLs in the tumors.  To evaluate the role of CD11b+ 
stromal cells, MC57-SIY-Hi, SIY-Lo or parental cells were infused into the brains of mice.  Ten 
days later, all mice received an adoptive transfer of naïve 2C T cells and a subcutaneous 
injection of MC57-SIY-Hi cells to activate the transferred cells.  Two days following 2C T cell 
treatment, when T cells are extravasating into the brain tumors in large numbers and presumably 
interacting with stromal cells, mice were sacrificed and brains were excised.  CD11b+ cells 
purified from dissociated brain tumors were incubated with biotinylated 2C-m67 TCR 
monomers.  Flow cytometry analysis showed that CD11b+ cells purified from MC57-SIY-Hi 
brain tumors presented SIY peptide bound to Kb on their surface (Figure 2.7A, right panel).  
However, no increase in surface levels of SIY/Kb was detectable on CD11b+ cells purified from 
SIY-Lo brain tumors (Figure 2.7A, middle panel).  CD11b+ cells from parental (SIY-negative) 
brain tumors served as a negative staining control (Figure 2.7A, left panel).  Tumor peptide was 
therefore cross-presented by CD11b+ tumor stromal cells to 2C T cells infiltrating MC57-SIY-Hi 
brain tumors two days post-transfer, but not on CD11b+ cells from MC57-SIY-Lo brain tumors.  
Figure 2.7B shows 2C-m67 TCR staining of two independent CD11b+ cell isolations from 
MC57-SIY-Lo brain tumors which stain similarly to CD11b+ cells from MC57 parental tumors 
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(12.7, 15.6,  and 12.1 MFU respectively), while two independent CD11b+ cell isolations from 
MC57-SIY-Hi brain tumors express significantly higher levels of SIY/Kb on the cell surface 
(64.9 and 84.3 MFU).  The percentage of dead CD11b+ stromal cells in SIY-Hi and SIY-Lo 
tumors two days following injection of 2C T cells were also compared and no differences were 
observed (data not shown).  Whether bystander elimination of antigen loss variant cells in 
MC57-SIY-Hi tumors occurred as a result of increased 2C T cell killing of stromal cells cross-
presenting SIY peptide could not be confirmed, perhaps because stromal cell killing occurs later 
than the point at which CD11b+ cells were collected for this experiment (two days after T cell 
transfer).  2C T cells only begin to appear in the brain between one to three days following 
adoptive transfer.  However, direct assessment of the ability of brain tumor APCs to cross-
present tumor-derived peptides demonstrated that cross-presentation can and does occur in the 
brain when sufficient tumor antigen is available. 
 
Activated 2C CTLs can also suppress the growth of SIY-expressing tumors without direct 
cancer cell recognition, possibly by targeting CD11b+ stromal cells cross-presenting SIY 
peptide 
To further examine whether stromal cell cross-presentation of tumor antigen enhances 
tumor elimination, we characterized the 2C T cell response to allogeneic H-2k PRO4L-SIY 
tumors in the brain.  Despite the inability of 2C T cells to directly recognize SIY peptide on the 
cancer cell surface due to MHC mismatch, activated 2C T cells had potent anti-tumor effector 
function in these mice with high antigen-expressing tumors.  PRO4L-SIY cells were infused into 
the brains of H-2b C57BL/6 RAG1-/- mice.  Seven days later, naïve 2C T cells were adoptively 
transferred into the mice.  Half of the mice were also received a small subcutaneous inoculation 
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of MC57-SIY-Hi cells to activate the T cells.  In all cases, the subcutaneous MC57-SIY-Hi cells 
did not grow out in the mice.  In the absence of the subcutaneous injection of MC57-SIY-Hi 
cells, no survival benefit was conferred by the adoptively transferred 2C T cells (Figure 2.8A).  
However, with the subcutaneous challenge of MC57-SIY-Hi cells to activate the adoptively 
transferred 2C cells, mice lived significantly longer than saline injected controls and 80% were 
cured, despite the lack of direct recognition of PRO4L-SIY cancer cells by 2C T cells (Figure 
2.8B). The response was antigen specific, because mice that were injected bilaterally with 
PRO4L-SIY cells and PRO4L-gp33 cells, which express an irrelevant peptide, showed delayed 
growth of PRO4L-SIY tumors only five days after adoptive transfer (Figure 2.8C, D).   
PRO4L-SIY and PRO4L-gp33 brain tumor tissue from untreated mice and mice that 
received 2C T cell adoptive transfers were immunostained using 4D11 antibody (anti-Ly-49G). 
Similar numbers of NK cells were observed in tumors of untreated mice and mice that received 
2C T cells one to three days following T cell transfer, and the number of NK cells was 
proportional to the size of the tumor, suggesting that NK cells may also participate in the 
clearance of PRO4L-SIY brain tumors following 2C T cell transfer.  However, the recruitment of 
NK cells to the brain was independent of the effect of T cell adoptive transfer (data not shown). 
 To determine if tumor peptides were cross-presented on CD11b+ stromal cells in this 
model of indirect T cell killing, we isolated CD11b+ cells from PRO4L-SIY brain tumors in mice 
that received either 2C T cell adoptive transfers or control lymphocytes from a C57BL/6 wild-
type mouse three days earlier.  Following incubation with biotinylated 2C-m67 TCR monomers, 
we were able to detect increased surface levels of SIY/Kb on CD11b+ cells from 2C T cell-treated 
mice compared to controls (Figure 2.9A).  To address whether 2C T cells were targeting 
CD11b+ stromal cells cross-presenting SIY peptide and killing the tumor stroma directly (and 
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PRO4L-SIY cells indirectly), we assessed the viability of CD11b+ stromal cells purified from the 
tumors.  Propidium iodide staining revealed proportionally higher percentages of dead CD11b+ 
cells in tumors pooled from mice that received 2C CTL adoptive transfers compared to C57 
wildtype lymphocyte transferred controls (Figure 2.9B, 40% vs. 25% respectively, calculated by 
% PI+CD11b+/all CD11b+).  
 Endothelial cells, another stromal cell type with the potential to cross-present tumor 
peptides, were analyzed by staining for expression of CD31/PECAM.  The smaller tumors in 2C 
T cell-treated mice had substantially reduced staining (Figure 2.10), but no attempt was made to 
determine whether this was a cause or an effect of the smaller tumor size in the treated mice. 
 
Discussion 
Our finding of a differential effect of adoptive T cell therapy on brain tumors expressing 
high or low levels of the target antigen supports the idea that stroma plays a role in T cell-
mediated rejection of brain tumors.  In the present experiments, activated CD8+ T cells were able 
to kill cancer cells expressing high or low levels of antigen efficiently both in vitro and in vivo, 
yet brain tumors expressing low levels of antigen recurred as a result of antigen loss variant 
cancer cells.   
In these studies, the tumor stroma was allowed to establish before initiation of treatment 
to best model the stromal environment T cells would encounter in an endogenously arising brain 
tumor.  Stromal cells with macrophage/microglia surface markers represent approximately one-
third of all cells in glioma biopsies 53,54 and between 5-35% of the total tumor burden in 
experimental rodent glioma models 55,56.  We were able to purify and characterize a population of 
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CD11b+ macrophage/microglia stromal cells representing approximately 10% of total tumor 
burden in the present experiments. 
From studies evaluating adoptive T cell therapy in peripheral tumor models, we know 
that cross-presentation of tumor antigens by stroma allows activated T cells to kill stromal cells 
46,47.  Using single-chain, high affinity TCR monomers, we have directly demonstrated that brain 
tumor CD11b+ stromal cells can cross-present tumor antigens at detectable levels in tumors 
expressing high levels of tumor antigen but not in tumors with low levels of antigen, and that 
these cross-presenting stromal cells are likely targeted and eliminated by antigen-specific, 
adoptively transferred T cells.   
Stromal cell cytolysis may enhance the therapeutic effect conferred by adoptively 
transferred T cells in three ways.  First, trophic support provided by stromal cells is eliminated.  
Stromal cells can enhance tumor growth by providing growth factors and stimulating 
angiogenesis.  Destruction of tumor stroma results in a less hospitable environment for residual 
cancer cells including ALVs that escape direct T cell killing and continue to proliferate.  Thus, 
cross-presentation of antigen by stromal cells could play an important role in preventing relapses.  
Second, elimination of stromal cells may remove a source of T cell suppression.  Stromal cells 
can serve as a physical barrier for tumor-infiltrating T cells and have multiple mechanisms for 
suppressing CTLs.  We did not examine the phenotype of the CD11b+ stromal cells in the 
present experiments, but in other tumor models we have found that cancer cells infused into the 
brain resulted in an influx of Gr1+ CD11b+ suppressor phenotype cells 57.  Elimination of these 
myeloid derived suppressor cells removes one form of suppression on tumor-infiltrating CTLs.  
Third, brain tumor stroma may provide a niche that supports chemoresistant and radiation-
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resistant cancer stem cells that express low or no MHC I or NK cell activating ligands on their 
surface 58.  Targeting tumor stroma may be an ideal way to eliminate these cells. 
In the present experiments, the extent to which tumors had progressed before T cell 
therapy was initiated determined whether a differential effect of T cells on the growth of high 
and low antigen-expressing tumors was observed.  Following adoptive T cell treatment on day 5 
after tumor cell infusion, both MC57-SIY-Hi and MC57-SIY-Lo tumors were established but 
treatable, and they initially regressed within 5 days.  If mice had been monitored for only 35 days 
when all mice still appeared healthy, it would have seemed that all mice were long-term 
survivors.  Instead, two mice relapsed from MC57-SIY-Lo tumors and were euthanized at 42 and 
54 days.  When the transfer of 2C T cells occurred on day 6 after tumor infusion, all of the 
MC57-SIY-Lo tumors recurred, with a median survival time of 65 days.  However, the MC57-
SIY-Hi tumors were completely cleared in nine of ten mice when the adoptive transfer occurred 
on day five or six after tumor infusion.  Finally, if T cell adoptive therapy was delayed until day 
10 following cancer cell infusion, it was too late for a therapeutic effect for either tumor, and 
mice died within the next four days with no prolongation of survival compared to untreated 
controls. Thus, at intermediate time points when tumors were well-established but treatable, the 
abundance of antigen available for cross-presentation may have prevented recurrences of the 
MC57-SIY-Hi tumors (9 of 10 long term survivors), and the scarcity of antigen made it more 
likely that recurrences would occur in the MC57-SIY-Lo tumors (only 3 of 10 long term 
survivors). 
Two lines of evidence, histological evaluation and calculations of tumor growth patterns, 
suggest that T cells initially cleared nearly all of the cancer cells from the brain. Following T cell 
therapy at the most effective time point, there was no clear histological evidence of tumor on day 
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ten, five days after T cell transfer.  Calculated estimations of tumor growth are consistent with 
the idea that very few cancer cells remained at that time point. The median survival time for 
untreated bilateral tumor mice was 14 days, and 17 days for unilateral tumors, in the absence of 
T cell therapy.  If there were only a single surviving cancer cell after the T cell treatment, with a 
doubling time of 24 hrs it would take two weeks to re-establish the original tumor inoculation 
and another two to three weeks to grow to a size of approximately one cm3, the point of 
producing neurological symptoms.  In cases of recurring MC57-SIY-Lo tumors, we were able to 
demonstrate that the cancer cells were antigen loss variants.  It may be that the residual tumor 
stroma nurtured a few antigen loss variant cells and allowed them to repopulate the tumor.   
Our experiments with allogeneic PRO4L-SIY tumors suggest that activated T cells can 
clear an established brain tumor by targeting the tumor stroma, without any direct recognition of 
the cancer cells.  PRO4L-SIY tumors cannot be directly killed by 2C T cells but do provide SIY 
peptide for cross-presentation on stromal cells.  Cross-presentation of brain tumor peptides to 
CD4 T cells 59 and CD8 T cells 60 has been previously reported, inferred from experiments of 
MHC mismatch between T cells and tumor cells.  In the present experiments, we were able to 
directly detect cross-presentation of tumor antigen on CD11b+ stromal cells using single-chain, 
high affinity TCRs, as well as demonstrate the apparent targeting and killing of these cross-
presenting stromal cells.   
PRO4L-SIY brain tumor growth was controlled following an adoptive transfer of 2C T 
cells, and the response was tumor specific because the growth of PRO4L-gp33 tumors was not 
affected by 2C T cells.  Indeed, activated 2C T cells were able to completely eliminate PRO4L-
SIY tumors from the brain.  This is in contrast to peripheral tumor models where an equilibrium 
was established between the transferred T cells and residual PRO4L-SIY cells 47 and tumors 
 67
grew out in mice that were subsequently depleted of CD8+ T cells.  Plautz et al. 59 observed a 
similar phenomenon with CD4 T cells adoptively transferred into mice bearing MCA tumors in 
the brain, which do not express MHC II, but were nevertheless eliminated by T cell treatment.   
In addition to killing stromal cells, it is unknown whether other effector mechanisms are 
involved in 2C T cell rejection of PRO4L-SIY brain tumors.  We did not examine the possibility 
that the degree of NK cell cytotoxicity may be changed in the presence of activated CD8+ T 
cells, but we did observe similar numbers of NK cells in PRO4L-SIY tumors with or without 
adoptive T cell therapy.  However, it is possible that NK cells may have been more cytotoxic in 
the presence of 2C T cells interacting with cross-presenting stromal cells.  Shanker et al. 61 
observed that CD8+ T cell transfer resulted in the rejection of antigen-negative cancer cell 
variants by a mechanism dependent on NK cells, and Wu et al. 58 demonstrated that IFNγ 
produced by T cells causes glioma stem cells to become susceptible to NK cell killing.   It is thus 
possible that the interaction of 2C T cells with cross-presenting stromal cells also enhances NK 
cell function, allowing rejection of allogeneic PRO4L-SIY cells but not PRO4L-gp33 cells.  This 
possibility warrants further investigation.  
In addition to stromal microglia/macrophages, other elements of tumor stroma may be 
targets of T cells.  Liver endothelial cells are able to cross-present antigens from apoptotic tumor 
cells 62,63.  We observed a reduction of in the number endothelial cells in PRO4L-SIY brain 
tumors of mice treated with 2C T cells.  This could be a consequence of the reduced tumor size, 
but requires further study. 
With respect to therapeutic implications of these results, targeting tumor stroma in 
addition to malignant cancer cells may help prevent tumor recurrence.  In peripheral tumor 
models, low antigen-expressing tumors can be damaged by radiation or chemotherapy to produce 
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a surge of antigen available for cross-presentation, and an appropriately timed adoptive T cell 
treatment can become more effective 46.  The present results suggest such a strategy may be 
effective for brain tumors expressing endogenous levels of antigen as well.  Other strategies for 
delivering tumor antigen, for example via viral vectors, could also enhance T cell targeting of 
stroma and help prevent tumor recurrence.  
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Figure 2.1  
MC57 cancer cell lines that express equiva-
lent levels of class I MHC Kb but differ in 
expression of SIY peptide are killed equally 
well by 2C T cells in vitro.   
A.  MHC I levels detected by anti-Kb staining.  
PRO4L-SIY cells are H-2k and therefore nega-
tive for anti-Kb staining.   
B.  Cell surface levels of SIY peptide bound to 
Kb detected by 2C-m67 TCR monomer staining.  
C.  SIY peptide expression levels correlate with 
eGFP expression.   
D.  2C T cells kill MC57-SIY-Hi and MC57-
SIY-Lo similarly in vitro.  Chromium release 
was measured from cancer cells incubated with 
preactivated 2C T cells at different effector to 
target ratios in triplicate.  Parental MC57 cells 
were used as a control.  All experiments were 
repeated at least three times and representative 
data are shown. 
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Figure 2.2  
Following adoptive transfer and activation in vivo, 2C T 
cells infiltrate all MC57 brain tumors and rapidly clear 
both MC57-SIY-Hi and SIY-Lo tumors.  Equivalent 
numbers of 2C T cells and tumor destruction were ob-
served in all SIY-Hi and SIY-Lo tumors at each timepoint 
so representative images were chosen.  Red = 2C T cells 
stained with 1B2 clonotypic antibody.  Blue = DAPI coun-
terstain.  Scale bar = 200 μm for all images.  n = 2 mice per 
group.         
A.  One day following 2C T cell transfer (6 days following 
infusion of SIY-Lo cancer cells into the brain).          
B.  Three days following 2C T cell transfer (8 days follow-
ing infusion of SIY-Lo cancer cells into the brain).    
C.  Five days following 2C T cell transfer (10 days follow-
ing infusion of SIY-Hi cancer cells into the brain).           
D.  In vivo activation of 2C T cells is required.  Five days 
following 2C T cell transfer (10 days following infusion of 
SIY-Hi cancer cells into the brain) but omitting the s.c. in-
fusion of SIY-Hi cancer cells on day 5.   
E.  Tumor infiltration by 2C T cells is SIY peptide-
independent.  Five days following 2C T cell transfer (10 
days following infusion of parental MC57 cancer cells into 
the brain). Mice also received a s.c. infusion of SIY-Hi 
cancer cells on day 5 to activate 2C T cells.   
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Figure 2.3  
Regression of both MC57-SIY-Hi and SIY-Lo brain tumors after 2C T cell transfer. 
A.  One day after 2C T cell transfer (6 days after bilateral infusion of SIY-Hi and SIY-Lo can-
cer cells into striatum) the tumors were similarly well-established.                                                      
B.  Five days after 2C T cell transfer (10 days after bilateral infusion of cancer cells into stria-
tum) both tumors appear to have been eliminated.  Arrows indicate former location of tumors.   
C. and D.  Quantitation of the size regression of both SIY-Hi and SIY-Lo brain tumors after 2C 
T cell transfer.  Mice with bilateral tumors received 2C T cells and a small s.c. infusion of SIY-
Hi cells on day 5 and were euthanized on day 6 (1 day after 2C transfer), day 8 (3 days after 2C 
transfer), or day 10 (5 days after 2C transfer). Both SIY-Hi and SIY-Lo tumors regressed within 
5 days of receiving 2C T cells.  n= 4 to 8 mice per group at each timepoint.  Two way ANOVA 
of treatment and time, significant interaction, p <0.001;  Bonferroni comparison of 2C vs. con-
trol on day 5, p < 0.001. 
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Figure 2.4  
Effect of adoptively transferred 2C T cells on survival of 
mice bearing unilateral or bilateral MC57-SIY-Hi and 
MC57-SIY-Lo brain tumors.   
A.  Median survival of untreated mice with unilateral brain 
tumors was 16 days for SIY-Hi and 17 days for SIY-Lo.  
Median survival was 18 days for parental MC57 mice given 
2C T cell transfers.  Mice with SIY-Hi or SIY-Lo tumors 
lived significantly longer when treated with 2C T cells five 
days following infusion of cancer cells, compared to no treat-
ment (p < 0.01).  Approximately 80% of mice with SIY-Lo 
brain tumors relapsed and died; median survival was 46 
days.  100% of SIY-Hi tumor mice were cured by 2C T cell 
treatment.  Survival of SIY-Hi mice that received 2C T cells 
differed significantly from SIY-Lo mice that received 2C T 
cells (p < 0.05).                                                                      
B-D.  Effect of adoptively transferred 2C T cells on survival 
of mice bearing bilateral brain tumors.  2C T cells eliminated 
SIY-Hi tumors, but some SIY-Lo tumors recurred in the 
same mice.  Each mouse treated with 2C T cells is repre-
sented by two curves.  When mice reached criteria for eutha-
nasia, brains were examined histologically to determine 
which tumor proved lethal.  The therapeutic effect of 2C T 
cells decreased with a delay in treatment as tumors became 
larger.   In mice with bilateral tumors that did not receive 2C 
T cells, both tumors progressed rapidly and mice had a me-
dian survival of 14 days. The “no 2C” mice (n=2) in B-D are 
the same.                                                                                
B.  When 2C T cells were injected on day five, SIY-Hi tu-
mors were eliminated in all mice, but two mice eventually 
succumbed to SIY-Lo tumor recurrences.  No tumor was 
evident histologically in the SIY-Hi hemisphere.  p < 0.01 
for SIY-Hi vs. SIY-Lo.                                                          
C.  When 2C T cells were injected on day six, one mouse 
died due to the SIY-Hi tumor, whereas four of five mice suc-
cumbed to SIY-Lo recurring tumors.  p < 0.01 for SIY-Hi vs. 
SIY-Lo.                                                                                   
D.  When 2C T cells were injected on day ten, a therapeutic 
effect was not observed for either tumor.  
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Figure 2.5 
Adoptively transferred 2C T cells persist in mice that relapse from recurring MC57-SIY-
Lo brain tumors.  Mice infused in the brain with MC57-SIY-Lo cancer cells received 2C T 
cell transfers and s.c. MC57-SIY-Lo cell infusions to activate 2C T cells on day 5.  Tissues 
were collected when mice (n=3) reached criteria for euthanasia following relapse 34 to 35 days 
later.  Immunostaining with 1B2 antibody demonstrated persistence of 2C T cells in all mice.  
Representative images are shown.  Red = 2C T cells stained with 1B2 clonotypic antibody.  
Blue = DAPI counterstain.  A.  Brain tumor, scale bar = 1 mm.  B.  Spleen, scale bar = 200 
μm.  C.  Draining cervical lymph node, scale bar = 200 μm. 
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Figure 2.6 
Recurring SIY-Lo brain tumors arise from variant cells that do not express SIY peptide.  
Explanted tumor cells from mice that relapsed from MC57-SIY-Lo brain tumors following 
adoptive transfer of 2C T cells (n=5)  were evaluated for MHC I expression with anti-Kb anti-
body and for SIY/Kb expression with 2C-m67 TCR monomer staining.   
A.  Tumors that recurred expressed normal levels of Kb.                                                            
B.  Tumor cells no longer expressed measurable surface levels of SIY/Kb recognized by 2C T 
cells.  Cultured parental MC57 cells and MC57-SIY-Lo cells were used as negative and posi-
tive controls respectively.  
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Figure 2.7 
CD11b+ stromal cells in MC57-SIY-Hi brain tumors but not SIY-Lo brain tumors cross-
present tumor antigens on MHC I.  CD11b+ cells were purified from established MC57, 
SIY-Lo and SIY-Hi brain tumors two days after adoptive transfer of 2C T cells and stained 
with 2C-m67 TCR monomers to detect SIY/Kb cross-presentation.               
A.  Representative plots of purified, dual-stained (with anti-CD11b Abs and biotinylated 2C-
m67 TCR monomers) brain tumor APCs from MC57, SIY-Lo and SIY-Hi brain tumors.                  
B.  2C-m67 TCR staining of independent samples of purified live CD11b+ cells collected 
from different mice demonstrated that detectable levels of cross-presentation of SIY peptide 
on CD11b+ stromal cells occurs only in tumors with high levels of available tumor antigen 
(MC57-SIY-Hi).  Staining levels of CD11b+ cells from MC57-SIY-Lo brain tumors were in-
distinguishable from those of CD11b+ cells from parental MC57 tumors.  Two brain tumors 
were pooled per sample, two samples per group were evaluated.   
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Figure 2.8 
Activated 2C CTLs cannot directly recognize H-2k expressing PRO4L-SIY brain tumors 
but are able to significantly prolong survival and achieve cures in tumor-bearing mice. 
A.  In the absence of a s.c. inoculation of MC57-SIY-Hi cancer cells, 2C T cell transfer had no 
effect on survival of mice bearing PRO4L-SIY brain tumors (n= 5 per group).   
B.  With a concurrent s.c. inoculation of MC57-SIY-Hi cancer cells, 2C T cell transfer signifi-
cantly prolonged survival of mice with PRO4L-SIY brain tumors (n = 5 per group, p < 0.01).  
Brains were examined for residual tumor, but none was found in the long-term survivors.         
C and D.  Growth inhibition by 2C T cell adoptive transfer was specific to PRO4L tumors ex-
pressing SIY peptide.  Mice received bilateral cancer cell infusions of PRO4L-SIY and PRO4L-
gp33 in the brain, followed by 2C T cell transfer on day five.  Mice were euthanized on day 10 
(five days after 2C transfer).  Brain tumor volumes were reconstructed by quantifying tumor 
areas of randomly selected sections of PRO4L-SIY tumors in (C.) and PRO4L-gp33 tumors in 
(D.)   n=8 for 2C and n=5 for control, p < 0.05 for PRO4L-SIY 2C vs. control. 
A B 
C D 
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Figure 2.9 
CD11b+ stromal cells from PRO4L-SIY brain tumors cross-present tumor peptide follow-
ing 2C T cell adoptive transfer.  Mice with established PRO4L-SIY brain tumors were adop-
tively transferred unactivated 2C T cells or control wildtype lymphocytes and given a s.c. infu-
sion of MC57-SIY-Hi cells to activate T cells on day seven.   
A.  2C-m67 TCR monomer staining detected higher levels of cross-presentation of SIY peptide 
by CD11b+ cells in tumors of mice treated with 2C T cells than in mice that received control 
lymphocyte transfers.   
B.  Proportionally more CD11b+ stromal cells were dead (based on propidium iodide uptake), 
possibly due to T cell killing in PRO4L-SIY brain tumors of mice that received 2C T cell trans-
fers compared to controls (40% vs. 25% respectively, % PI+CD11b+/all CD11b+). 
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Figure 2.10 
Endothelial cell staining (CD31+/PECAM+)  is reduced in PRO4L-SIY brain tumors of 
mice treated with 2C T cells.  Mice bearing PRO4L-SIY brain tumors were treated with 2C T 
cells and injected s.c. with a small burden of PRO4L-SIY cells on day five to activate 2C T 
cells, and euthanized on day ten.  Brain sections were stained with a biotinylated antibody 
against CD31/PECAM, and visualized with SA-594.  The area of endothelial cell staining was 
reduced in the 2C T cell treated mice (A) compared to control mice that did not receive 2C T 
cell adoptive transfers (B).  Scale bars = 200 μm.  C.  The mean area of stained vessels was 
quantified.  n= 8 for 2C T cell treatment, n=5 for controls.  One to two random brain tumor sec-
tions per mouse were analyzed.  p < 0.01 for 2C T cell treatment. 
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CHAPTER 3.  EVALUATION OF TUMOR-SPECIFIC ADOPTIVE T CELL THERAPY 
AND ONCOLYTIC VIROTHERAPY FOR THE TREATMENT OF METASTATIC 
MELANOMA BRAIN TUMORS 
Abstract 
 Brain metastases commonly arise in patients diagnosed with melanoma and significantly 
shorten survival.  Adoptive transfer of T cells recognizing melanoma-associated antigens has 
shown clinical success, but immune editing of tumors by T cells can result in antigen loss variant 
(ALV) cell outgrowth and tumor escape.  We evaluated a novel strategy to overcome tumor 
escape using a combination therapy of adoptive T cell transfer and administration of oncolytic 
myxoma virus (MYXV) in a syngeneic murine B16.SIY melanoma brain tumor model.  MYXV, 
a poxvirus with strict species tropism for European rabbits, is nonpathogenic in mice and humans 
but can infect and kill many mouse and human cancer cell lines including melanoma.  We 
evaluated the ability of recombinant MYXV expressing Tomato red fluorescent protein to infect, 
spread, and persist in B16.SIY brain tumors.  We also characterized the brain cytokine and 
immune cell responses to the virus.  B16.SIY cells were infected and killed by MYXV in vitro, 
but several lines of evidence indicate that the brain immune response to the virus limited its 
oncolytic ability in vivo.  Intratumoral injection of MYXV led to the robust expression of 
Tomato red protein that remained restricted to the tumor but waned after several days, recruited 
large numbers of CD11b+ macrophages/microglia and GR-1+ neutrophils to the tumor, and led to 
the production of IFNβ and TNFα by surrounding normal brain tissue.  Adoptive transfer of 
activated CD8+ 2C T cells that recognize SIY peptide presented on B16.SIY cells resulted in a 
doubling in survival time, but tumors recurred and no longer expressed SIY.  We tested the 
safety and efficacy of co-administering 2C T cells, MYXV, and neutralizing antibodies against 
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IFNβ to mice with established brain tumors.  Mice that received the combination therapy lived 
significantly longer than those receiving any single treatment, with no apparent spreading of the 
virus outside the tumor or other safety concerns, but mice eventually relapsed due to ALV 
outgrowth.  A small amount of infectious virus was recovered from the relapsed tumors, 
suggesting that strategies to improve viral replication and cell-to-cell spread in vivo via inhibition 
of additional cytokines or immune cells could further improve the survival outcome.     
 
Introduction 
 Metastatic brain tumors have been identified as the most common cause of death in 
patients with cutaneous melanoma1.  Cancer cells metastasize to the brain in greater than 50% of 
patients, leading to a median survival of three to four months.  Melanoma brain tumors are 
generally resistant to chemotherapy2 and typically recur following surgery, chemotherapy and 
whole or partial brain irradiation3,4.  In combination, these traditional therapies extend the post-
diagnosis median survival to approximately eight months.   
 Adoptive T cell immunotherapy is currently the most successful treatment option for 
patients with metastatic melanoma5.  Almost 50% of patients with metastatic melanoma show an 
objective response (partial or complete) after lymphodepletion with non-myeloablative 
chemotherapy and subsequent infusion of autologous, activated tumor-infiltrating T cells.  This 
response rate can be improved to 52-72% upon addition and dose escalation of total body 
irradiation prior to T cell infusion.  Almost 13% of treated patients (n=12 of 93) in recent clinical 
trials conducted by Rosenberg, Dudley and colleagues at the National Cancer Institute had 
complete responses and survived at least 18 months with ongoing responses as long as 75 
 85
months5.  Importantly, responses were observed in patients with metastases at various sites, 
including the brain6.   
 Successful T cell therapy for metastatic melanoma relies on the expansion of autologous 
tumor-infiltrating T cells ex vivo away from suppressive cells and cytokines before re-infusion 
into the patient.  T cells are typically isolated from tumors following surgical resection, expanded 
and activated ex vivo to 1010 or 1011 total cells, and infused back into the patient.  Prior to 
adoptive transfer, patients undergo lymphodepletion to eliminate competition with endogenous T 
cells for cytokines and space, and to eliminate Tregs5,7.  In some cases, the transferred cytotoxic 
T cells initially control tumor growth, but selective pressure edits the tumors until only cancer 
cells that lack the antigen or MHC molecule recognized by the T cells remain.  Recurrent tumors 
are comprised of antigen loss variant (ALV) cancer cells and escape T cell killing.  Many clinical 
and preclinical studies evaluating both adoptive T cell therapy and tumor peptide vaccine 
approaches have documented tumor escape due to immune editing of the tumor8-12, including in 
brain tumors13,14, and highlight the importance of targeting ALV cancer cells14-16.  Data from our 
own laboratory suggest that an appropriate strategy would be to enhance cross-presentation of 
tumor antigen on brain tumor stromal cells, leading to the elimination of these support cells for 
ALVs by cytotoxic T cells14.   
 Our previous work showed that adoptive transfer of tumor-specific T cells as a single 
therapy was effective, but not sufficient to cure established murine brain tumors.  Concurrent 
delivery of an oncolytic virus to a tumor could complement adoptive T cell therapy.  Oncolytic 
viruses have the potential to enhance anti-tumor responses in several ways:  tumor-specific viral 
infection may lead to oncolysis, the production of pro-inflammatory cytokines, release of tumor 
antigen to stimulate an immune response, recruitment of different immune cells, and in the case 
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of recombinant viruses, tumor-specific delivery and expression of therapeutic genes.  We chose 
to characterize the oncolytic potential of myxoma virus (MYXV), a replication-competent 
poxvirus with strict species tropism for European rabbits17,18.  MYXV can infect many human 
and mouse cancer cells and has a large dsDNA genome with the capability to deliver therapeutic 
eukaryotic genes (at least 25 kb)19-25.  The species barrier to MYXV replication depends on intact 
Type I interferon responses26, but mouse cancer cells with mutations that disrupt production of 
these cytokines become permissive to infection by MYXV.  MXYV tropism for mouse and 
human cancer cells also depends on hyperphosphorylation of the serine/threonine kinase Akt22,27.  
Mouse and human cancer cells can be categorized as permissive, semi-permissive, or non-
permissive according to their relative Akt activation.  Rapamycin can activate Akt through an 
mTOR-dependent pathway, and rapamycin treatment can increase the replication of MYXV in 
cancer cells in vitro and in vivo, but does not convert normal cells or non-permissive cancer cells 
to replication-permissive cells21,22,28.   
 Mouse and human melanoma and glioma cells are both permissive to infection by 
MYXV20,22,29,30.  Stanford and colleagues demonstrated improved survival of C57BL/6 mice 
with B16-F10 melanoma lung tumors by concurrent administration of MYXV and rapamycin22.   
MYXV treatment has also been shown to significantly improve survival of CD-1 nude mice 
implanted in the brain with several human glioma cell lines20.  While this xenograft model 
demonstrated proof-of-concept, characterization of MYXV in a syngeneic, immune-competent 
mouse brain tumor model has not been reported.  Due to the inherent immunogenicity of viruses, 
this is an essential test relevant to the translational potential of any oncolytic virotherapy. 
 In the present studies, we characterized the in vitro and in vivo ability of MYXV to infect, 
replicate, express a virally-delivered gene (tdTomato red fluorescent protein), and kill mouse 
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B16-F10 melanoma cancer cells expressing the model tumor antigen SIYRYYGL (B16.SIY) 
recognized by the 2C T cell receptor.  We also evaluated the combination therapy of adoptive 
CD8+ 2C T cell transfer and MYXV treatment in mice with established B16.SIY brain tumors.  
Lymphopenic C57BL/6 RAG1-/- mice lacking endogenous T and B cells were used to imitate the 
lymphodepletion protocol used in clinical trials evaluating adoptive T cell therapy.  All innate 
immune cells are normal in these mice.  We show that injection of MYXV into mice with 
established B16.SIY brain tumors is safe and leads to infection and virally-delivered gene 
expression.  We also characterized the cytokine and immune cell response to brain tumor 
injection of MYXV to evaluate its oncolytic capabilities in vivo in a syngeneic mouse melanoma 
model.  Our experimental findings differed significantly from published reports using xenograft 
models of brain tumors20, highlighting the importance of choice of model.  We also tested the 
safety and efficacy of intratumoral administration of neutralizing antibodies against interferon-β 
(IFNβ) and found modest survival benefits when mice received MYXV, 2C T cells, and anti-
IFNβ.    
  
Methods 
Cells 
 B16-F10 mouse melanoma cells were purchased from ATCC.  B16.SIY cancer cells were 
a gift from Dr. Thomas Gajewski (University of Chicago).  Parental B16-F10 murine melanoma 
cells were transduced to express the model peptide antigen SIYRYYGL (SIY) fused in frame 
with GFP and expressed as a fusion protein as previously described31.  2C T cells collected from 
2C TCR transgenic mice recognize SIY peptide in the context of MHC I Kb. Cancer cells were 
grown in DMEM containing 5 mM HEPES, 10% FCS, 1.3 mM L-glutamine, 50 pM 2-ME, 
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penicillin, and streptomycin.  RK-13 rabbit kidney cells used to propagate and titer MYXV were 
a gift from Dr. Richard Moyer (University of Florida, Gainesville).  RK-13 cells were 
maintained in minimum essential medium (MEM) with Earle’s salts supplemented with 2 mM 
glutamine, 50 U/mL penicillin G, 50 µg/mL streptomycin, 1 mM sodium pyruvate, and 0.1 mM 
nonessential amino acids (MEM-C; Mediatech, Manassas, VA).   
 
Virus 
 The Lausanne strain of myxoma virus (MYXV) was a gift from Dr. Richard Moyer. 
Recombinant MYXV-Red was provided by Dr. Grant McFadden (University of Florida, 
Gainesville).  Both viruses were propagated using RK-13 cells.  MYXV-red expresses tdTomato 
red fluorescent protein under the control of a synthetic vaccinia virus early/late promoter and was 
originally designated vMyx-tdTr24.  Virus replicated in RK-13 cells was sucrose pad purified 
prior to use in mouse experiments.  UV-inactivated MYXV was produced by exposing sucrose 
pad purified MYXV-Red to a standard tissue culture hood UV light overnight.  The inability of 
the UV inactivated virus to infect RK-13 cells was confirmed prior to use.  Uninfected RK-13 
cells also were sucrose pad purified and used as a control in vivo cytokine release experiments.  
 
In vitro infection of cancer cells by MYXV 
 Adherent cancer cells at ~75% confluency were incubated with virus suspended in MEM-
C without serum at different multiplicities of infection (MOI, ratio of infectious virions:cells) at 
37°C in 5% CO2 for 1 hr, with rocking at 15 min intervals.  Similarly, mock-infected cells were 
incubated in MEM-C without serum.  In some experiments, the inoculum was removed and cells 
were washed with PBS three times before adding fresh DMEM with 10% serum.  For other 
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experiments, fresh DMEM with 10% serum was added after 1 hr and virus remained.  For the 
pre-incubation survival experiment, cells were washed, trypsinized and prepared for brain 
injection after 1 hr incubation with virus at MOI=1.   
 
Virus recovery from mouse tissues 
 For titration of infectious virions within tissue samples, samples were frozen then thawed 
three times, sonicated for 1 to 5 min, and then a series of 10-fold dilutions were made.  Each 
dilution (400 μL) was added to confluent RK-13 cells in 35 mm diameter plates.  After 1 hr of 
incubation at 37°C in 5% CO2 with rocking at 15 min intervals, 3 mL of a 1:1 mixture of 1% 
SeaKem high gelling temperature agarose solution and 2× MEM-C with 20% serum was added 
to the infected cells.  Plates were incubated at 37°C in 5% CO2 for 5 to 7 days until viral foci 
(plaques) developed.  A minimum of three separate series of 10-fold dilutions were processed to 
calculate the average number of viral plaque forming units per mL (pfu/mL; virus titer) in each 
sample. 
 
Cell Viability Assay 
 B16.SIY cells growing in 96 well plates were infected at a MOI=1 or 10 with wild-type 
MYXV or mock-infected.  The CellTiter-Blue Viability Assay (Promega) was used according to 
the kit instructions.  Viable cells convert a redox dye (resazurin) into a fluorescent end product 
(resorufin) that can be detected at 590nm.  Blue reagent was added 1.5 hrs prior to fluorescence 
readings.  All measurements were done in at least triplicate and the assay repeated twice.  
Brightfield images of cytopathic effect were taken immediately prior to adding blue reagent to 
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wells and were acquired using a Leica DMI 4000 B microscope (magnification ×100) and 
ImagePro Express software (Media Cybernetics). 
 
Mice 
 C57BL/6 and C57BL/6 RAG1-/- mice originally from The Jackson Laboratory are 
maintained as colonies at the University of Illinois.  2C TCR transgenic mice are maintained as a 
heterozygous colony by crossing with C57BL/6 mice and screened for expression of the 2C TCR 
on PBLs by flow analysis with 1B2 clonotypic antibody.  Mice were 2–6 months of age at the 
time of experiments. All procedures were approved by the Institutional Animal Care and Use 
Committee at the University of Illinois at Urbana-Champaign.   
 
Intracranial cancer cell infusions 
 Cancer cells were trypsinized and collected, washed twice with Hanks Balanced Salt 
Solution (HBSS), and stereotaxically infused into the brain while the mice were anesthetized 
using Isoflurane gas.  Mice received an infusion of 2 x 103 B16.SIY cells in 300 nL HBSS into 
ventral striatum (AP 0.5mm, lat 2.5mm, DV -4mm).  In some experiments, mice received 
bilateral infusions of cancer cells.  Mice were sacrificed according to standard criteria for 
euthanasia:  75% of baseline body weight or signs of neurological impairment, in accordance 
with IACUC guidelines.   
 
Preparation of activated 2C T cells for adoptive transfer 
 2C T cells from spleens and lymph nodes of 2C TCR transgenic mice were prepared by 
mechanical dissociation of the tissues and ammonium chloride buffer lysis of erythrocytes.  
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Lymphocytes were incubated for 48 hrs with 3 μM SIY peptide (SIYRYYGL) and 5% RCAS to 
activate effector 2C T cells.  Cells were then collected using PBS/EDTA buffer and washed with 
HBSS.  Mice were briefly restrained under a heat lamp and 1-2 x 106 cells in 200μl HBSS were 
injected into the tail vein.  
 
Histological analysis of 2C T cell response in brain 
 Mice were sacrificed at two or seven days following 2C T cell transfer or followed for 
survival.  Brains and cervical lymph nodes were collected and snap-frozen.  1B2 monoclonal 
antibody specific for the 2C TCR was purified from the hybridoma and biotinylated in our 
laboratory.  Unfixed 10 μm tissue sections were stained with 1B2 antibody amplified with 
HRP/tyramide-biotin (Perkin Elmer) and detected with streptavidin-Alexa 594 (Invitrogen), and 
counterstained with DAPI (Invitrogen). 
 
Flow cytometry experiments 
 Cancer cells were trypsinized and washed twice with PBS/0.5% BSA before analysis of 
GFP expression on a BD FACS Canto instrument.  For analysis of cross-presentation, CD11b+ 
cells were isolated from ten day-old B16-F10 or B16.SIY brain tumors injected with 5x106 pfu 
MYXV-Red or PBS three days earlier.  Tumor hemispheres from two mice were pooled per 
sample.  Tumors were minced and dissociated by tituration following a 30 min incubation in 
Hibernate A media (BrainBits) containing Dispase (5U/mL).  Cells were then pushed through 
100 μM and 40 μM filters sequentially. Erythrocytes were lysed with ACK buffer.  CD11b+ cells 
were isolated via positive selection using magnetic microbeads labeled with anti-CD11b 
antibodies (Miltenyi Biotec) and passing the cell mixture over LS columns in a VarioMACS 
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magnet.  Cells were washed with PBS/1% BSA and stained with anti-CD11b antibody directly 
labeled with Pacific Blue (Caltag Laboratories) and 2C-m67 TCR multibiotinylated monomers 
detected with streptavidin-allophycocyanin (Invitrogen).  Expression and purification of soluble, 
single-chain 2C-m67 TCR monomers that bind SIY/Kb with low nanomolar affinity were 
described previously16.  Monomers were chemically biotinylated at multiple sites via free amine 
groups using EZ-Link NHS-PEO4 Biotinylation Kit (Pierce).   
 
Intratumoral injection of MYXV and characterization of infection in vivo 
 Mice with four- to eight-day established B16.SIY brain tumors (depending on 
experiment) were anesthetized and injected intratumorally with approximately 5x106 pfu of 
sucrose pad-purified MYXV in 0.7 μL total volume.  For some experiments, brains were 
collected and snap-frozen in OCT media, immersion fixed in 10% formalin, or homogenized and 
used for cytokine ELISA experiments or to recover infectious virus.  Brains required formalin 
fixation for preservation of Tomato red protein expression.  Sections were counterstained with 
DAPI and analyzed with an Olympus fluorescence microscope.  
 
Immunostaining and qualitative analysis of brain tumor-infiltrating immune cells 
 RAG1-/- mice with 5 day-old B16.SIY brain tumors were injected intratumorally with 
MYXV, UV-MYXV or PBS.  Mice were sacrificed 48 hrs later and brains were snap-frozen for 
cryosectioning.  10 μm sections were fixed in cold 95% ethanol for 20 min, rinsed with PBS, and 
blocked with Superblock (Pierce) for 4 hrs prior to incubation with primary antibodies.  Slides 
were stained overnight with purified anti-mouse CD11b (BD Pharmingen), anti-mouse 4D11 
(BD Pharmingen) or anti-mouse GR-1 (Becton Dickenson).  Slides were then washed with PBS 
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+ 0.1% Tween and incubated with rabbit anti-rat-biotin (Vector) with 5% normal rabbit serum 
for 2 hrs, washed, and incubated with streptavidin-Alexa594 (Invitrogen) for 20 min.  Sections 
were also co-labeled with DAPI (Invitrogen).  Images were taken using Texas red and blue filter 
sets.  Control slides omitting each primary antibody were negative for Alexa594. 
 
Cytokine ELISAs 
 Mouse TNFα Ready-Set-Go ELISA kits (eBiosciences) and mouse IFNα and IFNβ 
ELISA kits (PBL Biomedical Labs) were used according to manufacturer instructions.  Brain 
tumors from mice were homogenized in 2 ml ice cold PBS + 0.1% Igepal detergent and pooled, 
two brains per sample.  Supernatants were concentrated and tested in triplicate.   
 
Interferon β neutralizing antibodies 
 Rabbit polyclonal antibody against mouse IFNβ (PBL Interferon Source) was diluted in 
sterile saline and injected into mice intratumorally as a single dose (12.5 ng in 0.5 μL) or 
intraperitoneally at 100 μg/kg body weight diluted in 100 μL sterile PBS once daily for four 
days. 
 
Data Analysis 
 GraphPad Prism software was used for all statistical analyses:  cell viability data by two-
way ANOVA, survival curves by Log-rank test, cytokine ELISAs by one-way ANOVA and 
unpaired t test.   Significance was considered p < 0.05.  
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Results 
B16.SIY melanoma cancer cells are permissive to infection by MYXV  
 The murine melanoma cell line B16-F10 is known to be permissive to MYXV infection 
and replication22.  In collaboration with Dr. Amy MacNeill and Dr. Rosalinda Doty (University 
of Illinois at Urbana-Champaign), we extended this finding by testing the permissiveness of 
B16.SIY cancer cells derived from the parental B16-F10 line that express the model antigenic 
peptide SIYRYYGL.  Two methods were used to confirm that MYXV can productively infect 
and replicate in B16.SIY cancer cells in vitro.  First, both mature and immature virion stages 
were observed in infected cells by electron microscopy and confirmed intracellular viral 
trafficking and replication (data not shown, unpublished data from AM & RD). Second, multi-
step growth curves demonstrated productive viral replication after inoculation of cells at a low 
multiplicity of infection (MOI), implying cell-to-cell spread over the first 48 hrs post-infection 
(p.i.), and an exponential increase in infectious virions.  Similar kinetics of virus replication were 
observed in permissive RK-13 cells, B16-F10 cells, and B16.SIY cells (data not shown, 
unpublished data from AM & RD). 
 
MYXV infection of B16.SIY melanoma cancer cells results in oncolysis 
 To determine whether MYXV has oncolytic effects on B16.SIY cancer cells in vitro, we 
infected confluent monolayers of cells at a MOI=1 or 10 to observe the cytopathic effect and 
measure cell viability.  By 24 hrs, most cells rounded up or detached from the plates and by 48 
hrs, significant numbers of cells detached from the wells at both MOIs compared to mock-
infected cells (Figure 3.1).  By 72 hrs post-infection, only a few viable cells were evident at the 
highest MOI.  Mock-infected cells remained adherent and overgrew the wells by 72 hrs.   
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 To quantitatively assess the decrease in cell viability following infection with MYXV, we 
measured the metabolic activity of infected cells over time using a commercially available 
fluorescence based assay (Figure 3.2).  Mock-infected cells continued to multiply over 72 hrs 
with a corresponding increase in metabolic activity.  At MOI=1, viability was significantly 
decreased by 48 hrs p.i.  At MOI=10, viability was significantly decreased by 24 hrs p.i.  Over 
72 hrs, the viability of melanoma cells infected at both MOIs remained low, but some cancer 
cells did survive.   
 
Survival duration of mice with B16.SIY brain tumors increases significantly following 
adoptive transfer of 2C T cells 
 B16.SIY cancer cells express low to no class I MHC on their surface and are not 
efficiently killed by 2C T cells in vitro31.  However, the in vivo antitumor efficacy was not 
known.  We tested the effect of transferring activated CD8+ 2C T cells that recognize SIY 
peptide presented on the MHC class I molecule Kb into mice with established B16.SIY brain 
tumors.  We hypothesized a potential effect due to homeostatic proliferation of the transferred 
cells in lymphopenic animals, so both RAG1-/- and wild-type C57BL/6 mice were infused with 
B16.SIY cells in the brain.  On day seven when the tumors were well-established, mice received 
intravenous injections of preactivated 2C T cells and were followed for survival (Figure 3.3).  
Control mice that were injected with saline died within two weeks (median survival of RAG1-/- 
mice was 14 days, C57BL/6 mice 13 days) while mice that received 2C T cells survived over 
twice as long (median survival of RAG1-/- mice was 35 days, C57 mice 30 days).  However, no 
mice were cured by T cell adoptive therapy alone.   
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2C T cells infiltrate and initially destroy brain tumors, but tumors recur and no longer express 
SIY tumor antigen 
 The ability of transferred 2C T cells to control tumor growth and increase survival 
duration, but not successfully eliminate the tumors, led us to further characterize the timecourse 
of response.  Mice with seven day-established B16.SIY brain tumors received intravenous 
injections of activated 2C T cells and were euthanized two or seven days after transfer.  
Immunostaining with 1B2 antibody specific for the 2C TCR revealed low numbers of 2C T cells 
in the tumors on day two, but a massive infiltration of 2C T cells in the tumors on day seven 
(Figure 3.4).  The T cells were restricted to the tumor bed and were not found in surrounding 
normal brain tissue.  Tumors were mostly necrotic and had lost clear margins by day seven.  
Lymph nodes also contained large numbers of T cells at both timepoints, while untreated RAG1-
/- control mice had none (data not shown).  Immunostaining was also done on brains collected 
when mice reached criteria for euthanasia.  2C T cells were absent from the large tumors 
comprising almost the entire hemisphere of the brain.  However, 2C T cells were present in the 
draining cervical lymph nodes, but in much smaller numbers than those observed on day seven 
(data not shown). 
 The presence of an early anti-tumor T cell response that disappears in late-stage tumors 
led us to hypothesize that the tumors may have recurred from outgrowth of antigen loss variant 
(ALV) cancer cells that are not recognized by 2C T cells.  When mice reached criteria for 
euthanasia, brain tumors were collected and mechanically dissociated.  Cells were then cultured 
for four to seven days to enrich for live cancer cells and analyzed by flow cytometry (Figure 
3.5).  GFP expression was used as a surrogate marker for expression of SIY peptide as these 
genes are fused in frame and expressed as a fusion protein.  Tumor explant cells from four mice 
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were compared to fresh B16.SIY cells and parental B16-F10 cells that do not express GFP.  All 
cancer cells recovered from the brain tumors had lost expression of GFP indicating that ALV 
outgrowth led to tumor recurrence in the mice.   
 
Intratumoral injection of MYXV into established brain tumors results in tumor-specific 
infection and viral gene expression 
 To evaluate whether concurrent delivery of MYXV could complement adoptive T cell 
therapy, we characterized the oncolytic effects of MYXV in vivo.  MYXV-Red was injected 
directly into established B16.SIY brain tumors to assess safety and characterize the timecourse 
and spread of viral infection.  Intratumoral injection of virus resulted in robust expression of 
Tomato red fluorescent protein in the tumor but not in surrounding normal brain tissue 24 hrs 
following injection (Figure 3.6A).  Some cancer cells expressing Tomato red protein could be 
found up to eight days post-injection, but expression peaked at 48-72 hrs post-injection (data not 
shown).   UV-inactivated MYXV was used as a control and expression of Tomato red protein 
was not observed in tumors at any time (Figure 3.6B).  We also tested the ability of live MYXV 
to spread to contralateral brain following intratumoral injection in a bilateral tumor model.  We 
did not observe any spread of virus to contralateral brain tumors (Figure 3.6B).  Peripheral 
tissues were collected and homogenized one to five days post-injection of virus and titered to 
check for spread of virus outside the brain.  Live virus was not detected in blood, spleen, liver or 
lymph nodes in any mice (n=9).   In all experiments, mice did not exhibit any behavioral 
abnormalities or weight loss following injection of live or UV-inactivated virus into the brain.  
Intratumoral injection of MYXV in the brains of semi-immunocompetent mice was safe and 
resulted in transient, tumor-specific infection and gene expression. 
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Pre-infection of B16.SIY cancer cells prior to infusion leads to modest increases in survival 
 To further characterize the oncolytic effects of MYXV in vivo, we evaluated whether 
virus treatment could improve the survival of mice infused in the brain with B16.SIY cells that 
were pre-incubated with a low MOI (=1) of MYXV-Red.  2 x 103 pre-infected or mock-infected 
cells, or a 1:1 mixture of both (2 x 103 total), were injected into the brains of RAG1-/- mice 
(Figure 3.7).  Mice injected with either 50% or 100% pre-infected cells lived significantly longer 
than mice that received mock-infected cells (18 and 20 days vs. 15 days, respectively, p < 0.05), 
but there were no long-term survivors.  Mice injected with only 1 x 103 mock-infected cancer 
cells were included for comparison to mice injected with 2 x 103 50% pre-infected cells to 
determine if all infected cells were killed, and to test the ability of the virus to spread from 
infected cells to non-infected neighboring tumor cells leading to additional oncolysis.  There was 
a small increase in survival of the 50% pre-infection group compared to the 1 x 103 mock group, 
but the difference was not statistically significant (18 vs. 16 days, respectively, p = 0.096).  
Despite initial infection of the cancer cells with a low MOI, our results demonstrated modest 
oncolytic effects by MYXV and suggest potent anti-viral mechanisms exist in vivo that hinder 
the replication and spread of virus. 
 
Strong cellular immune response to MYXV-Red may promote clearance of virus and prevent 
oncolysis 
 The striking difference we observed regarding the oncolytic ability of MYXV in vitro 
and the modest survival advantage conferred in vivo may be attributed to immune clearance or 
inactivation of the virus.  Expression of Tomato red protein was observed out to eight days post-
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injection, but only in a few cancer cells, suggesting that MYXV can readily infect tumor cells, 
but does not spread due to physical barriers or anti-viral immune mechanisms triggered in the 
brain that abort viral replication.  
 To characterize the cellular immune response to the virus, RAG1-/- mice with five day-
old B16.SIY brain tumors (n=12) were injected intratumorally with live MYXV-Red, UV-
inactivated MYXV-Red or PBS (n=4 per group).  Brains were collected after 48 hrs and sections 
were stained for the immune markers CD11b (on macrophages and microglia), GR-1 (on 
neutrophils) and Ly49G2 (on NK cells).  In a parallel experiment, brains were formalin fixed and 
prepared for H&E staining.  The immunostained tissues revealed a large infiltration of CD11b+ 
and GR-1+ cells in tumors injected with live or UV-inactivated virus, especially adjacent to the 
virus injection site   (Figure 3.8).  We do not believe these cells are dual-labeled myeloid-
derived suppressor cells that express these phenotypic markers because equivalent H&E stained 
sections showed local microabscesses created by an influx of inflammatory cells, typically 
macrophages and neutrophils, in the same location (data not shown).  The pathology was limited 
to the virus injection site in all cases.  CD11b+ cells were also found around the rim of all tumors 
including those injected with PBS.  GR-1+ cells and NK cells were only found in tumors injected 
with live or UV-inactivated virus.  NK cells were found very rarely. 
 
Brain cytokine response to MYXV may also restrict spread of virus 
 In addition to immune cell clearance of the virus, production of cytokines by immune 
cells and normal non-tumor brain cells may abort viral replication and spread and prohibit the 
robust infection of a tumor.  To characterize the cytokine response in vivo in response to 
intratumoral injection of virus, eight day-old B16.SIY brain tumors growing in RAG1-/- mice 
 100
were injected with MYXV-Red, a mock preparation from uninfected RK-13 cells, or PBS.  24 
hrs later, tumors were excised and homogenized and the supernatants were tested for IFNβ, 
IFNα, and TNFα by ELISA (Figure 3.9).  We observed significant increases in brain levels of 
both IFNβ and TNFα in response to virus.  There was no detectable change in IFNα.  Data are 
normalized to PBS-injected brain samples.  The cytokine response was virus-specific because the 
mock preparation of virus (a sucrose pad- purified extract of RK-13 cells used to propagate the 
virus) did not elicit a response that was different from that of PBS.   In addition, the cytokine 
response to MYXV injection in mouse brain was similar whether or not a tumor was present 
(data not shown).  We did not attempt to characterize the cell types responsible for the 
production of these cytokines.  
 
Treatment with neutralizing antibodies against IFNβ is safe and modestly improves survival of 
mice treated with a combination of MYXV and adoptive 2C T cell transfer  
 Based on the cytokine profile characterizing the pro-inflammatory response to MYXV in 
the brain, we considered whether cytokine neutralization could be an appropriate strategy to 
pursue in vivo.  Due to the known anti-tumor effects of TNFα, we selected a strategy of treating 
tumor-bearing mice with MYXV-Red and neutralizing antibodies against IFNβ, rather than 
suppressing the TNFα response.  We tested the safety of this approach in short-term experiments 
followed by survival experiments to determine the efficacy.   
 RAG1-/- mice with seven day-established B16.SIY brain tumors were injected 
intratumorally with MYXV-Red.  At the same time mice received intratumoral (i.t.) or 
intraperitoneal (i.p.) injections of polyclonal neutralizing antibodies, or both.  Intraperitoneal 
injection of neutralizing antibodies against IFNα has been shown to be effective for decreasing 
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brain cytokine levels32.  Brains were collected, fixed and sectioned two or four days after 
treatment.  In all mice, the expression of Tomato red protein remained limited to the tumor and 
did not spread to surrounding normal brain cells after any combination of treatment (Figure 
3.10).  At four days post-injection of virus, strong expression of Tomato Red protein was still 
observed in tumor.  No differences were noted in the expression of Tomato Red protein in mice 
that received i.p. or i.t. delivery of neutralizing antibody. 
 After determining that co-administration of neutralizing antibodies against IFNβ and 
MYXV did not result in infection of normal brain, we evaluated the effect of a combination 
therapy on survival of mice with established B16.SIY brain tumors.  Mice received an 
intratumoral co-injection of MYXV and anti-IFNβ Abs on day six, intravenous injections of 
activated 2C T cells on day seven, and intraperitoneal injections of anti-IFNβ Abs for four days 
following virus administration (Figure 3.11).  Mice that received MYXV, anti-IFNβ Abs and 2C 
T cells lived three times longer than untreated mice (39 vs. 13 days, respectively), and 
significantly longer than mice receiving only 2C T cells (39 vs. 32 days, p<0.05 Log-rank test).  
Injection of anti-IFNβ alone increased survival time modestly (15 vs. 13 days) but the difference 
was not statistically significant.  Data are pooled from two separate experiments.  
 It was unknown whether MYXV was cleared over time from the brain tumors, or if the 
virus was inactivated but still present in the tumors.  When mice in the survival experiments 
reached criteria for euthanasia, brain tumors were excised and tumor homogenates were tested to 
determine whether MYXV-Red could be recovered from the tumors several weeks after 
injection.  Tumor homogenates were titered on permissive RK-13 cells using a plaque forming 
assay (Figure 3.12).  A small number of infectious MYXV-Red virions were recovered from 11 
of 14 total tumors tested.  This effect was time-dependent and more virus was isolated from 
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tumors of mice that died two weeks after injection than from mice that survived several weeks 
after injection.   
 
A subset of CD11b+ stromal cells purified from B16.SIY brain tumors cross-present SIY 
peptide but MYXV-infection does not increase cross-presentation 
 We tested the hypothesis that MYXV infection of B16.SIY brain tumors would lead to 
oncolysis and release of tumor peptides for cross-presentation.  We purified CD11b+ cells from 
B16.SIY tumors 72 hrs after intratumoral injection of MYXV-Red and analyzed surface levels of 
SIY/Kb complexes using single-chain 2C-m67 TCR multibiotinylated monomers (Figure 3.13).  
MYXV-injected B16-F10 tumors and PBS-injected B16.SIY tumors were used as controls.  A 
subset of cross-presenting CD11b+ cells were detected in B16.SIY brain tumors compared to 
B16-F10 tumors, but there was no difference between MYXV and PBS injected tumors at 72 hrs 
post-injection.   
     
Discussion 
 T cells are exceedingly proficient at antigen-specific killing, but successful elimination of 
any tumor requires concurrent destruction of both antigen-expressing and ALV cancer cells.  Our 
experiments confirmed that immune editing by T cells occurs in the brain, and allows ALV cells 
to repopulate a tumor.  2C T cell killing of B16.SIY melanoma cells in vitro is inefficient31, 
presumably due to low MHC I expression, thus it was unknown if adoptive transfer of activated 
2C T cells would have any beneficial effect on controlling aggressive B16.SIY tumors in vivo.  
Impressively, 2C T cells almost completely eliminated established brain tumors and significantly 
improved survival time, but the primary cause of death in all mice was outgrowth of ALV cancer 
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cells.  These studies have identified a realistic model of metastatic melanoma ideal for testing 
strategies to eliminate ALV cancer cells from brain tumors.  
 To better understand the low levels of 2C T cell killing previously observed in vitro31 
compared to our results in vivo, we treated B16.SIY cells with IFNγ for 24 hrs to test for 
upregulation of MHC I.  Cell staining and flow cytometry analysis revealed strong upregulation 
of both MHC I Kb and SIY/Kb complexes (data not shown).  We assume IFNγ release from 
activated T cells in the brain leads to upregulation of MHC I by tumor cells resulting in efficient 
killing, though this remains to be tested.   
 Lymphodepletion prior to adoptive T cell therapy has proved critical to the successful 
persistence and effector function of transferred T cells in preclinical and clinical studies33-35.  We 
observed a modest increase in survival of RAG1-/- mice lacking endogenous T cells and B cells 
compared to wild-type mice following T cell transfer (35 vs. 30 days respectively), but the 
sample sizes were small (n=3).  All subsequent experiments were done using only RAG1-/- mice.  
It is interesting to note that it took more than two days following adoptive transfer for activated T 
cells to arrive in the brain in large numbers, but in less than five days the fast-growing tumors 
were mostly dissolved and only a small necrotic core was evident. 
 Many potential approaches could be used to target ALV cancer cells.  We tested whether 
a relatively novel oncolytic virus, MYXV, could augment the efficacy of adoptive T cell therapy 
and prevent outgrowth of ALV cells.  We hypothesized that MYXV could enhance T cell 
therapy for melanoma brain tumors by four potential mechanisms.  First, MYXV can directly kill 
melanoma cancer cells (including ALV cells) and has the potential to replicate and spread within 
the tumor, but not to normal brain tissue, making MYXV very safe.  Second, the large dsDNA 
genome of MYXV can accommodate the insertion of large eukaryotic genes.  The present 
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experiments demonstrated viral gene delivery and robust expression of Tomato red fluorescent 
protein.  Our laboratory is currently engineering MYXV to express therapeutic genes such as 
mIL-15/mIL-15Rα, a cytokine and its receptor subunit important for T cell activation, 
persistence, and anti-tumor effector function of CD8+ T cells and NK cells.  Third, MYXV tumor 
infection can lead to local production of immunostimulatory cytokines and recruit innate and 
adaptive immune cells to aid in tumor clearance.  Fourth, dying cancer cells killed by MYXV 
may be a source of tumor peptides that could be cross-presented on brain APCs to further 
enhance a T cell response. 
 Previous work in our laboratory using a different SIY-expressing brain tumor showed 
that T cell elimination of cross-presenting CD11b+ stromal cells prevented the outgrowth of 
ALV cells and cured mice with established brain tumors14.  We hypothesized that oncolysis by 
MYXV could lead to antigen release and cross-presentation.  In the present studies, we were 
unsuccessful in our attempts to demonstrate increased levels of cross-presentation of SIY peptide 
on CD11b+ stromal cells following intratumoral injection of MYXV.  This may be due to choice 
of timing (3 days after injection of virus when Tomato red expression peaks) or the mechanism 
of cell death.  MYXV probably kills cancer cells via apoptosis, but this has not yet been 
confirmed.  It is unknown if apoptotic removal of cancer cells would generate enough peptide to 
produce detectable cross-presentation. 
 MYXV can productively infect and replicate in B16.SIY melanoma cells in vitro, 
resulting in cell death.  In the brain, MYXV can safely and selectively infect tumor but not 
normal brain.  In one experiment when the virus injection missed the tumor by several 
millimeters and was instead infused adjacent to the lateral ventricle, we observed Tomato red 
expression in ependymal cells (which has been previously reported for other oncolytic viruses36) 
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but it disappeared by four days post-injection.  Peripheral organs (lung, heart, intestine, spleen, 
kidney, reproductive tract, and liver) were also tested for infectious virus at one, two, three and 
five days post-injection by incubating tissue homogenates with RK-13 cells and analyzing for 
expression of Tomato red protein.  No virus was detected in any sample (n=2 or 3 at each 
timepoint). 
 MYXV had potent and persistent oncolytic effects leading to long-term survival in 
several xenograft mouse tumor models including brain tumors20,21,25.  In contrast to these 
findings, the oncolytic effects of MYXV in our syngeneic brain tumor model were substantially 
diminished.  Viral expression of Tomato red protein in the tumor was present 24 hrs post-
injection and peaked by 48-72 hrs, but then rapidly disappeared and only a few infected cells 
were observed at one week.  Proximity to the virus injection site was important.  Fewer infected 
cells were observed at distant sites within the tumor, but infection of cultured cells at a low MOI 
allowed viral spread, suggesting impaired spread of the infection in vivo.  We characterized the 
oncolytic ability of MYXV in both immunocompetent and lymphopenic RAG1-/- mice.  We 
observed similar levels of Tomato red expression, innate immune cell recruitment, and survival 
in both strains of mice.  We attribute, at least in part, the modest oncolytic effect of MYXV in 
vivo to the presence of anti-viral cytokines (IFNβ and TNFα) produced by surrounding brain or 
immune cells in response to the virus.  Macrophages/microglia and neutrophils are also recruited 
to the tumors and may have a role in viral clearance or inhibition of replication.  Our survival 
experiment using pre-infected cancer cells suggests that these mechanisms are very potent.      
 We did observe a small but significant survival benefit from our combination therapy of 
T cell transfer and administration of MYXV and anti-IFNβ antibodies. Infusion of neutralizing 
antibodies against IFNβ was safe and did not lead to the productive infection of normal cells 
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outside the tumor.  Infectious virions were recovered from most brain tumors, even several 
weeks following injection, supporting the hypothesis that overcoming local inactivation of the 
virus would improve the spread of infection.   
 We are exploring several strategies that could potentially enhance the oncolytic effects of 
MYXV in vivo.  TNFα in combination with IFNβ are known to synergize to produce an anti-viral 
state37-39.  Transient, local neutralization of TNFα within the brain by antibodies or other agents 
has been shown to be safe40,41 and is a possible strategy in addition to IFNβ neutralization to 
improve viral replication for at least a few days.  The pre-infection survival experiment in the 
present studies used a very low MOI and the survival benefit was small, but an initial infusion of 
more viral particles should improve the extent of infection.  Practical limitations on the volume 
of virus that can be injected intracranially could be skirted if MYXV was delivered intravenously 
and sufficient amounts reached the brain.  The blood brain barrier is likely to be leaky enough to 
allow virus to enter a tumor42 and we plan to purify large amounts of virus to test intravenous 
administration.   
 Several recent studies have revealed significant synergistic effects of treating tumor-
bearing animals with an oncolytic virus, including MYXV, and rapamycin or rapamycin 
derivatives21,22,43,44.  Rapamycin is under active investigation for treatment of many types of 
cancer45 and is FDA approved for treatment of renal cell carcinoma.  A recent report documented 
beneficial responses in patients with melanoma co-treated with rapamycin and chemotherapy46.  
Rapamycin is best known for its immunosuppressive effects and can suppress T cell rejection of 
organ transplants.  We plan to test if co-treatment of mice with low doses of rapamycin and T 
cell adoptive transfer would improve viral spread but spare T cell effector functions.  Finally, 
MYXV-mediated delivery and expression of therapeutic genes would be an ideal way to 
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transiently express tumor antigens or other immune modulators in the brain that could enhance 
cross-presentation and promote tumor clearance by innate immune cells such as NK cells, 
potentially resulting in the elimination of ALV cancer cells.   
 We evaluated a novel strategy using MYXV to target syngeneic brain tumors and 
complement adoptive T cell therapy.  The safety, tumor-selectivity, and robust expression of 
virally delivered genes by MYXV support its further investigation as a cancer therapeutic. 
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Figure 3.1   
Cytopathic effects of MYXV infection on B16.SIY cells in vitro.  Cells were mock-infected 
or infected at a MOI=1 or 10.  Images were taken over 72 hrs post-infection.   
Left column, mock infected:  The adherent monolayer of cells becomes more confluent over 
24 to 72 hrs.  Cells are overgrown by 72 hrs and multiple cell layers are evident.   
Middle column, infected at MOI=1:  Cells begin to round up and detach by 24 hrs.  Some 
cells do remain adherent at 72 HPI.   
Right column, infected at MOI=10:  Clear cytopathic effect and very few cells remain adher-
ent at 72 hrs.  All images taken using 10x objective, 100x total magnification. 
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Figure 3.2 
B16.SIY cell viability decreases following infection with MYXV in vitro.  Viable cells con-
vert a redox dye (resazurin) into a fluorescent product (resorufin) that can be detected at 590nm. 
Cells were infected at a MOI=1 or 10, or mock-infected.  Measurements were taken over 72 
hours post-infection (p.i.).  Mock-infected cells continued to multiply resulting in an increase in 
fluorescence over time.  At MOI=1, viability was significantly decreased at 48 and 72 hours p.i.  
At MOI=10, viability was significantly decreased at 24, 48 and 72 hrs p.i.  p<0.05 for two-way 
ANOVA with Bonferroni post-test.  Data are representative of two independent experiments. 
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Figure 3.3 
Adoptive transfer of activated, tumor-specific 2C T cells significantly increases survival 
duration of both wild-type C57BL/6 and lymphopenic RAG1-/- mice with established 
B16.SIY brain tumors.  Mice were infused with 2x103 B16.SIY cells in the brain and tumors 
were allowed to establish for seven days prior to treatment.  Mice then received intravenous in-
jections of approximately 1x107 activated 2C T cells or saline and were followed for survival.  
Both C57BL/6 and RAG1-/- mice treated with 2C T cells lived significantly longer than un-
treated controls (p < 0.05 Log-rank test), but no cures were achieved.  Survival of C57BL/6 and 
RAG1-/- mice treated with 2C cells (30 vs. 35 days respectively) were not significantly different 
(p = 0.1) so a small effect due to homeostatic proliferation of 2C T cells in lymphopenic RAG1-
/- mice was not conclusive.  Numbers on graph indicate median survival.   
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Figure 3.4 
Activated 2C T cells infiltrate and destroy established B16.SIY brain tumors within one 
week after transfer.  B16.SIY cells were infused into the brains of RAG1-/- mice.  On day 7, 
mice were injected with activated 2C T cells.  Mice were sacrificed on day two or seven after 
transfer (n=3 per group).  Brains were sectioned and stained with a clonotypic antibody against 
the 2C TCR.  A few 2C T cells can be observed in the tumors on day two (A), but a massive 
response is present on day seven (B) and the tumors are almost completely destroyed.  Red = 
2C T cells stained with biotinylated 1B2 antibody and detected with streptavidin-Alexa 594.  
Blue = DAPI counterstained cell nuclei.  Scale bar = 200μm.  Images are from two different 
mice per group.   
 
A.  Two days post-transfer of 2C T cells 
B. Seven days post-transfer of 2C T cells 
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Figure 3.5 
Cancer cells recovered from recurring B16.SIY brain tumors in mice treated with 2C T 
cells no longer express SIY peptide.  When mice reached criteria for euthanasia (all >30 days 
out), brain tumors were excised and dissociated.  Tumor cells were cultured in vitro for approxi-
mately one week to enrich for live cancer cells.  B16.SIY cells express enhanced green fluores-
cent protein (GFP) as a fusion protein with SIY peptide.  Loss of GFP expression was used as a 
marker for loss of SIY expression.  Cancer cells from four tumor explants were analyzed by 
flow cytometry.  All cancer cells were similar to parental B16-F10 melanoma cells that do not 
express GFP, indicating antigen loss (or antigen low) variant outgrowth in these mice.  Fresh 
B16.SIY cancer cells (not from a mouse tumor) were included as a positive control and ex-
pressed GFP at much higher levels.  All cancer cells retained expression of melanin confirming 
that the expanded tumor explant cells were cancer cells. 
B16-SIY 
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Figure 3.6 
Injection of MYXV-Red into established B16.SIY mouse brain tumors results in tumor-
selective infection and viral gene expression.  A.  Tomato Red fluorescent protein is ex-
pressed in B16.SIY cancer cells (GFP+ cells) but not in normal surrounding brain tissue 24 
hours after intratumoral injection of live virus into a four-day old tumor.  B.  Tomato Red pro-
tein is observed 24 hours after injection of live virus (left panel) but not after injection of UV-
inactivated dead virus (right panel) into bilateral B16.SIY brain tumors in the same mouse.  Top 
= brightfield, bottom = Texas Red filter.  All images taken using 10x objective, 100x total mag-
nification. 
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Figure 3.7 
Pre-incubation of B16.SIY cancer cells with MYXV-Red prior to infusion into the brain 
results in a modest increase in survival.  Cells were incubated with virus at a MOI=1 for 1 hr, 
washed, and prepared for injection.  2 x 103 pre-infected or mock-infected cells, or a 1:1 mix-
ture of both (2 x 103 total), were infused into the brains of RAG1-/- mice.  Three mice per group 
were followed for survival.  Mice that were injected with 2 x 103  cells that were either 50% or 
100% preinfected with MYX-Red lived significantly longer than mice injected with 2 x 103 
mock-infected cells (18 and 20 vs. 15 days respectively, p<0.05 for both by Log-rank test).  
Mice that received only 1 x 103 mock-infected cells were included for comparison to mice that 
received 2 x 103 cells that were 50% pre-infected to assess the ability of the virus to spread 
from infected cells to non-infected neighboring tumor cells.  There was a small increase in sur-
vival of the 50% pre-infection group compared to the 1 x 103 mock group, but the difference 
was not statistically significant (18 vs. 16 days, respectively, p = 0.096).  Numbers indicate me-
dian survival. 
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Figure 3.8 
Strong cellular immune response to intratumoral injection of live or UV-inactivated MYXV-Red.  Five day-
old B16.SIY brain tumors growing in RAG1-/- mice were injected with live virus, UV-inactivated virus or PBS.  48 
hours later, brains were collected, sectioned and stained for immune markers (CD11b on macrophages/microglia, 
GR-1 on neutrophils, Ly49G2 on NK cells).  All tumor sections from mice injected with UV-inactivated virus 
stained similarly to those that received live virus.  Only images with live virus are shown (A., C., and E.).  Scale 
bar = 200 μm.  Red= 1° Abs detected by Alexa594, Blue= DAPI.  A-B.  CD11b+ cell infiltration in B16.SIY brain 
tumors injected with (A.) MYX-Red and (B. ) PBS.  In all tumors, CD11b+ cells were found around the rim and 
scattered through the core, but were also found in massive numbers at the site of live or inactivated virus injection. 
(see right side of A.)  C-D. Large numbers of GR-1+ neutrophils in tumors injected with (C.) MXYV-Red but not 
(D.) PBS.  E.  NK cells were present in low numbers in tumors injected with MYXV-Red but not PBS.   
A. B. 
C. D. 
E. F. 
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Figure 3.9 
Intratumoral injection of MYXV-Red in-
creases local concentrations of IFNβ and 
TNFα but not IFNα.  Mice with eight day-
old B16.SIY brain tumors received intratu-
moral injections of MYX-Red, a mock 
preparation of the virus propogation cell 
line, or PBS.  At 24 hours, tumors and sur-
rounding brain tissue were excised, ho-
mogenized, and the supernatants were as-
sessed using cytokine ELISAs.  Horizontal 
lines indicate baseline response defined as 
cytokine release following intratumoral in-
jection of PBS.  P<0.05 by unpaired t test.  
Data from two separate experiments were 
pooled. 3 samples per group (MYXV, 
mock, PBS), two brains pooled per sample 
and normalized by tissue weight.     
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Figure 3.10 
MYXV infection remains restricted to the tumor and does not spread to normal brain fol-
lowing injection of neutralizing antibodies against IFNβ.  Mice with seven day-established 
B16.SIY brain tumors were injected intratumorally with MYXV-Red.  Mice received intraperi-
toneal (i.p.) injections of neutralizing antibodies at the same time for two consecutive days.  
Some mice were also injected intratumorally (i.t.) with anti-IFNβ on day seven.  Two or four 
days following treatment, brains were collected, fixed, and sectioned.  A.  Two days following 
i.p. injection of anti-IFNβ.  Normal brain at periphery of image where DAPI-stained nuclei are 
less dense does not express Tomato Red protein.  B.  Four days following i.p. injection of anti-
IFNβ.  Normal brain is not infected and approximately 20% of tumor is infected (expressing 
Tomato red protein).  Scale bar = 200 μm.  Three mice were analyzed per group.  Intratumoral 
administration of neutralizing antibodies had similar results (data not shown). 
A. 
B. 
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Figure 3.11 
Combination treatment of RAG1-/- mice with B16.SIY brain tumors leads to a small but 
significant improvement in survival time.  Mice with seven day-established brain tumors re-
ceived activated 2C T cells i.v., intratumoral injection of MYXV-Red, and neutralizing antibod-
ies (Abs) against IFNβ (single intratumoral and 4 days intraperitoneal injections).  Mice receiv-
ing MYXV with or without anti-IFNβ Abs did not survive longer than untreated historical con-
trols.  Mice treated with MYXV, 2C T cells, and anti-IFNβ Abs lived significantly longer than 
mice that received only MYXV and 2C T cells (39 vs. 32 days respectively, p < 0.05 by Log-
rank test).  Data from two separate experiments was pooled.  Numbers indicate median survival. 
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Figure 3.12 
Infectious MYXV-Red virions can be recovered from B16.SIY brain tumors weeks after 
intratumoral injection.  Brain tumors were excised when mice reached criteria for euthanasia.  
Tumor homogenates were titered on permissive RK-13 cells using a plaque forming assay.  
Each dot represents virus recovered from one mouse.  The range of recovered virus is approxi-
mately 50-5000 times less than number of infectious particles originally injected.  Data col-
lected with Dr. Amy MacNeill. 
0 10 20 30 40 50
1
10
100
1,000
10,000
days survived
PF
U
/m
g 
tis
su
e
123 
 
B16-SIY +  MYX-Red #1
100 101 102 103 104
100
101
102
103
104 30.64% 20.67%
46.83% 1.86%
B16-SIY +  MYX-Red #2
100 101 102 103 104
100
101
102
103
104
1.59%35.43%
19.75%43.23%
B16F10 + MYX-Red #1
100 101 102 103 104
100
101
102
103
104
0.61%32.80%
11.53%55.06%
B16F10 + MYX-Red #2
100 101 102 103 104
100
101
102
103
104
1.23%38.30%
14.99%45.48%
B16-SIY + PBS #1
100 101 102 103 104
100
101
102
103
104
4.41%54.60%
25.05%15.94%
B16-SIY + PBS #2
100 101 102 103 104
100
101
102
103
104 20.61% 20.75%
55.62% 3.02%
Figure 3.13    
MYXV infection did not increase cross-presentation of SIY peptide on CD11b+ cells at 72 hrs post-injection.  
Mice were injected in the brain with 1x104 B16-F10 or B16.SIY cancer cells.  On day 7, 5x106 pfu MYX-Red or 
PBS were injected intratumorally.  Three days later CD11b+ cells were isolated from dissociated tumor tissue using 
magnetic beads labeled with anti-CD11b antibodies.  CD11b+ cells were stained with anti-CD11b antibody and 
multibiotinylated 2C-m67 TCR monomers that recognize SIY/Kb.  Monomers were detected with streptavidin-
allophycocyanin.  Events are gated on live cells on the basis of propidium iodide exclusion.  Dead cells were not 
characterized.  Two samples per treatment, two brains pooled per sample.   
(A.)  Infection of B16.SIY brain tumors with MYXV-Red did not increase SIY peptide cross-presentation on tu-
mor CD11b+ stromal cells at 72 hrs compared to PBS injected controls (C.).  B16-F10 tumors were included as a 
control for non-specific binding (B.).  
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CHAPTER 4.  SUMMARY AND CONCLUSIONS 
 
 
 Adoptive T cell therapy following lymphodepletion is currently the most successful 
treatment for patients with metastatic melanoma and can mediate tumor regression in over 50% 
of patients, including those with brain metastases1.  Adoptive therapy for patients with 
glioblastoma has been less successful and future clinical trials should be designed to include 
some of the important criteria learned from (1) results of adoptive therapy trials for metastatic 
melanoma and (2) preclinical animal studies that demonstrate effective ways to prevent immune 
editing of tumors by antigen-specific T cells.   
 For example, patients with gliomas may require pre-conditioning with non-myeloablative 
chemotherapy or total body irradiation prior to adoptive therapy.  Transferred T cells should be 
highly reactive and CD4+ regulatory T cells (Tregs) should be actively excluded.  Furthermore, 
successful therapies will likely need to target multiple tumor antigens as well as tumor stromal 
cells that shelter ALV cells.  Inclusion of CD4+ T cells that can target MHC class II restricted 
tumor peptides on tumor stromal cells may be important in addition to CD8+ effector T cells.  
Information on glioma-associated antigens was previously lacking but these peptides can now be 
used to generate highly reactive antigen-specific T cells.  The field is moving towards identifying 
TCR genes specific for glioma antigens and viral transduction of autologous cells for adoptive 
transfer may be a possibility in the near future.  Finally, multimodal therapies will likely be 
critical to prevent tumor escape. 
 In the present studies, we evaluated the effects of 2C T cell adoptive therapy for MC57-
SIY-Hi and SIY-Lo mouse brain tumors growing in lymphopenic RAG1-/- mice to mimic the 
condition of lymphodepleted patients.  Activated 2C T cells could kill SIY-Hi and SIY-Lo 
cancer cells equally well in vitro and adoptively transferred 2C T cells were able to rapidly 
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eliminate both SIY-Hi and SIY-Lo established brain tumors.  The transferred T cells were naïve 
and required in vivo activation with a subcutaneous cell vaccine to gain effector function.  
Similar to the clinical situation, tumor recurrences were frequent and resulted from immune 
editing of tumors and not the lack of persistence by the transferred T cells.  T cell therapy led to 
the elimination of antigen-expressing tumor cells, but was only effective for eliminating antigen 
loss variant (ALV) cancer cells in certain cases.   
 Our experiments demonstrated that the level of tumor antigen present affects the success 
of adoptive T cell therapy with regard to ALV cells.  With high levels of antigen, tumor stromal 
cells such as microglia/macrophages present tumor peptide on their surface.  As a result, T cells 
directly eliminate cancer cells and probably kill cross-presenting stromal cells as well.  This was 
observed even in tumors in which there was no direct recognition of the tumor cells, yet adoptive 
T cell therapy led to the rejection of antigen-negative tumors and cured the mice.  While the 
exact mechanism by which stromal cells are mediating this effect in the brain is still unknown, T 
cell therapy for tumors expressing high levels of antigen did lead to the indirect elimination of 
ALV cells and cured mice with established tumors.  Much debate has surrounded the issue of 
whether brain tumor associated macrophages and microglia are capable of enhancing CD8+ T 
cell responses against brain tumors by cross-presenting MHC I restricted tumor peptides.  We 
were able to show the first direct evidence of tumor antigen cross-presentation on CD11b+ 
stromal cells in brain tumors using soluble high affinity single-chain T cell receptor monomers.   
 While patients are certainly unable to choose to have high expression of a tumor antigen, 
these findings suggest that strategies that target brain tumor stroma or increase antigen shedding 
from tumor cells to enhance cross-presentation may improve the clinical success of T cell 
adoptive therapies.  Both chemotherapy and irradiation are proven ways to induce local necrosis 
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and antigen shedding leading to enhanced cross-presentation2 and are already approved 
treatments for brain tumors.  An appropriately timed transfer of tumor-specific T cells could 
potentially be much more successful in combination with these therapies.  In support of this, 
treatment of mice with B16-F10 melanoma tumors with cyclophosphamide can lead to the 
release of tumor peptide and improve CD8+ cell cytotoxicity while also depleting Tregs from the 
tumor3.  In terms of combining multiple treatment modalities, cyclophosphamide could also 
eliminate innate immune cells responsible for clearing oncolytic viruses, making all of these 
therapies complementary.   
 We also characterized the effect of 2C T cell adoptive therapy on aggressive B16.SIY 
melanoma brain tumors.  Like many cancer cells, B16.SIY cells express very low levels of MHC 
I and 2C T cells have limited cytotoxic effects in vitro4.  It was unknown if adoptive therapy 
would have any effect in an in vivo tumor model.  Impressively, strong antigen-specific 
responses by 2C T cells were observed suggesting that activated T cells produce sufficient 
amounts of IFNγ to upregulate surface levels of MHC I.  Alternatively, RAG1-/- mice do have 
NK cells that can produce IFNγ, and we have not ruled out this possibility or a synergistic effect 
of NK and 2C T cells.  Furthermore, the preparation of cells for adoptive transfer did not exclude 
CD4+ T cells, another possible source of IFNγ (discussed more below).   
 This fast-growing tumor model provides a very brief therapeutic window of opportunity.  
Adoptive therapy led to more than a two-fold increase in survival time and similar to the MC57 
model, ALV cells repopulated the tumors leading to death.  2C T cells persisted in the mice, but 
could no longer recognize the tumors.  We did detect a small percentage of CD11b+ cells in the 
tumors that were cross-presenting SIY peptide on day 10, but this was in mice that did not 
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receive 2C T cells.  2C T cell killing may release additional peptide available for cross-
presentation.   
 We have not determined why MC57-SIY-Hi brain tumors are cured by 2C T cell 
adoptive transfer while B16.SIY brain tumors are not.  Based on levels of GFP expression that 
should be directly equivalent to levels of SIY expression, B16.SIY cells express similar if not 
higher levels of SIY than MC57-SIY-Hi cells.  However, we have not directly compared surface 
levels of SIY/Kb on these cell lines following IFNγ treatment.  There are several possible reasons 
for the survival difference, including the observation that activated 2C T cells express the 
inhibitory programmed death receptor PD-1 and upon stimulation with IFNγ, B16.SIY cells 
upregulate its ligand PD-L1.  It would be valuable to determine if PD-1 inhibition improved the 
antitumor response by 2C T cells.  We have also not characterized whether MC57 cancer cells 
express PD-L1.  Another potential reason that MC57-SIY-Hi tumors are easier to cure following 
adoptive 2C T cell transfer may be related to minor histocompability antigens.  MC57 cell lines 
are rejected by wild-type C57BL/6 mice without any intervention, but they do grow out in 
lymphopenic RAG1-/- mice.  We adoptively transfer a mixed population of cells including some 
CD8+ T cells that do not express the 2C TCR and instead express an endogenous TCR.  These 
cells may be able to eliminate MC57-SIY-Hi cells but not B16.SIY cells based on these antigens.     
     It would be simple to conclude from these experiments that activated CD8+ tumor-
specific T cells are solely responsible for the antitumor responses we observed in both models.  
However, careful consideration must be given to the population of T cells adoptively transferred 
into these mice.  Transferred cells were isolated from the lymph nodes of 2C TCR transgenic 
mice and activated in vitro with SIY peptide and cytokines for 48 hours prior to injection.  We 
characterized the activated transfer population and identified approximately 50% of the cells as 
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expressing the 2C TCR and CD8.  The remaining cells were approximately 5-10% CD4+ T cells 
(half of which are CD25+), 25% B cells, 4% NK cells and 6% CD11b+ cells (unpublished data).  
Furthermore, approximately 50% of the 2C T cells expressed the inhibitory receptor PD-1.  
Additional characterization of the critical components of the antitumor responses we observed is 
important. 
 We explored one potential mechanism to enhance T cell elimination of brain tumors by 
characterizing the oncolytic effects of myxoma virus in combination with adoptive therapy.  
Oncolytic virotherapy, while tumor-specific, is not antigen-restricted.  For example, productive 
infection by myxoma virus should not discriminate between antigen-positive or antigen-negative 
cancer cells, or even cancer stem cells, although this needs to be explored further.   
 Myxoma virus (MYXV) is a rabbit poxvirus with strict species tropism for European 
rabbits.  MYXV can also infect mouse and human cancer cell lines due to signaling defects in 
innate antiviral mechanisms and hyperphosphorylation of Akt5,6.  MYXV demonstrated 
impressive killing of human glioma cell lines in mouse xenograft brain tumors7.  Following 
injection of the same number of plaque forming units of MYXV into syngeneic B16.SIY brain 
tumors, we observed tumor-specific but abortive infection and evidence of immune clearance of 
the virus.  The combination of T cell adoptive transfer and myxoma virus injection resulted in a 
small but significant increase in survival time, but neutralization of the cytokine IFNα was 
required.  In the xenograft models, viral titer peaked two weeks after injection in the tumors and 
was detectable for more than 40 days.  We were also able to detect infectious virus particles in 
the brain several weeks after injection, but at very low titers.  Viral gene expression peaked at 48 
to 72 hours post-injection and then decreased rapidly.  We hypothesize that the difference in 
xenograft versus syngeneic graft tumor models may relate to the unresponsiveness of human 
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cancer cells to mouse Type I interferons produced in the mouse brain.  We are planning 
experiments to test this hypothesis. 
  Interestingly, many oncolytic viruses approved for clinical trials are not tested in 
syngeneic tumors growing in immune-competent animals prior to use in patients.  Given the 
sporadic objective responses in clinical trials of patients with malignant brain tumors thus far, 
and the allocation of millions of dollars for conducting these trials, this could perhaps be an 
important checkpoint for evaluating immunogenicity and improving efficacy preclinically. 
 There are many potential ways to enhance the oncolytic efficacy of MYXV and other 
oncolytic viruses in brain and peripheral tumors.  Based on the results of our experiments, two 
obvious strategies would be to enhance viral replication in infected tumor cells and limit the 
initial clearance of the virus by transiently depleting neutrophils and macrophages. Rapamycin 
has been shown to enhance viral replication in cancer cells6,8-11 and could help prevent abortive 
infections in vivo.  For example, we have injected MYXV-Red into mice with syngeneic GL261 
glioma brain tumors and expression of Tomato red protein is detectable in these tumors only 
after mice have been pretreated with rapamycin (unpublished data).  Rapamycin (also known as 
sirolimus) and rapamycin-derivatives are currently being evaluated in 159 different clinical trials 
for the treatment of many cancers (www.clinicaltrials.gov, accessed 11/22/09), and if approved, 
would potentially complement oncolytic virus strategies.  Neutrophils are likely responsible for 
phagocytosing extracellular virus and clearing it before it can be internalized by tumor cells.  
Transient host neutrophil depletion using anti-GR-1 antibodies has been shown to improve viral 
spreading in tumors12 and should be characterized in our tumor models prior to administration of 
MYXV-Red. 
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 Multi-modal combination therapies for brain tumors will likely require innate and 
adaptive immune participation.  Due to their impressive degree of tumor-specificity, oncolytic 
viruses such as myxoma virus may be ideal vectors for delivering therapeutic genes encoding 
additional tumor antigens for cross-presentation on tumor stromal cells or NK cell activating 
ligands (UL-16BP, MICA, Rae-1b/H-60 ligands)13.  Our laboratory is currently engineering a 
recombinant MYXV encoding mouse IL-15 and its receptor subunit IL-15Rα14.  In addition to 
the effects of IL-15 on improving antitumor responses by CD8+ T cells, IL-15 can recruit and 
activate NK cells that may be able to help eliminate ALV cancer cells15-18.  It would also be 
interesting to see if MYXV delivery of additional SIY peptide to a B16.SIY brain tumor would 
produce similar effects (cures) as seen in the MC57-SIY-Hi model due to cross-presentation.   
 Tumor-specificity is an important requirement of an ideal brain tumor therapy due to low 
cell turn-over in the brain.  Myxoma virus has demonstrated robust, tumor-specific gene delivery 
in established brain tumors.  Combined with the antigen-specificity of adoptively transferred T 
cells, this combination treatment should be further explored for treatment of malignant brain 
tumors.  
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